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A self-sustaining endocytic-based loop promotes
breast cancer plasticity leading to aggressiveness
and pro-metastatic behavior
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The subversion of endocytic routes leads to malignant transformation and has been impli-
cated in human cancers. However, there is scarce evidence for genetic alterations of endo-
cytic proteins as causative in high incidence human cancers. Here, we report that Epsin 3
(EPN3) is an oncogene with prognostic and therapeutic relevance in breast cancer.
Mechanistically, EPN3 drives breast tumorigenesis by increasing E-cadherin endocytosis,
followed by the activation of a β-catenin/TCF4-dependent partial epithelial-to-mesenchymal
transition (EMT), followed by the establishment of a TGFβ-dependent autocrine loop that
sustains EMT. EPN3-induced partial EMT is instrumental for the transition from in situ to
invasive breast carcinoma, and, accordingly, high EPN3 levels are detected at the invasive
front of human breast cancers and independently predict metastatic rather than loco-regional
recurrence. Thus, we uncover an endocytic-based mechanism able to generate TGFβ-
dependent regulatory loops conferring cellular plasticity and invasive behavior.
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Endocytosis is a critical regulator of several cellular processes,and its subversion is thought to play a role intumorigenesis1,2. Indeed, endocytic proteins, including
endocytic adaptors, Rab family members, and E3 ligases are
altered in different tumor types1. The link between endocytosis
and cancer is further strengthened by the observation that altered
vesicular trafficking of growth factor receptors and of integrin-
and cadherin-based adhesion complexes can lead to epithelial-to-
mesenchymal transition (EMT)3. EMT is a transcriptional pro-
gram associated with the acquisition of a motile/invasive state and
the emergence of cancer stem cells (CSCs), which drive tumor
initiation, progression, and metastasis4,5. Increasing evidence
supports the existence of intermediate EMT states (so-called
partial EMT) characterized by the concomitant presence of both
epithelial and mesenchymal features, offering a more dynamic
interpretation of the fluidity and plasticity of the EMT program6.
Indeed, intermediate EMT states have been identified as key
drivers of organ development and fibrosis, as well as cancer
progression5,6.
Epsin3 (EPN3), together with Epsin1 (EPN1) and Epsin2
(EPN2), belongs to the evolutionarily conserved epsin family7,8.
Whereas EPN1 and EPN2 are well-characterized endocytic
adaptors7, the function of EPN3 is largely unknown. Epn3
knockout mice did not display obvious phenotypes, likely due to
redundancy with other epsins9. Furthermore, while EPN1 and
EPN2 are ubiquitous, EPN3 is expressed at low levels in normal
tissues, except for gastric parietal cells9, arguing for specialized
functions. Notably, EPN3 expression is upregulated in wounded
epithelial tissues (e.g., ulcerative colitis) exhibiting altered
cell–extracellular matrix interactions8. High EPN3 levels were
also detected in migrating keratinocytes in cutaneous wounds, but
not in differentiating keratinocytes8. Finally, enforced EPN3
expression has been linked to increased cell migration10,11.
Here, we show that EPN3 is overexpressed in ~40% of breast
cancers (BCs) and that its overexpression (associated with gene
amplification in ~25% of the overexpressing cases) is an inde-
pendent predictor of distant metastasis. We further demonstrate
that EPN3 overexpression induces a state of partial EMT
(assessed by a variety of biological and biochemical phenotypes),
triggered by EPN3-dependent endocytosis of ECAD and sus-
tained through a feed-forward loop between ECAD internaliza-
tion and enhanced TGFβ signaling. Finally, EPN3 protein levels
are upregulated at the invasive front of human BCs that are
undergoing the in situ-to-invasive transition, and its expression is
required for the transition from in situ to invasive carcinomas in
model systems. These results identify EPN3 as an oncogene that
is frequently altered in BC and which acts as an independent
predictor of disease outcome.
Results
The EPN3 gene is amplified and overexpressed in BC. EPN3 is
located on chr. 17q21.33, 10.8 Mbps from ERBB2 (Fig. 1a). In
public databases, EPN3 is putatively amplified in ~7–8% of BCs,
and co-amplified with ERBB2 in around half of these cases
(Fig. 1b, left and middle). To obtain direct evidence of EPN3
amplification, we performed fluorescence in situ hybridization
(FISH) on an independent cohort of BC patients12,13 and found
EPN3 amplified in ~10% of the cases. EPN3 and ERBB2 were co-
amplified in ~5% of all cases, and individually amplified in ~5%
and ~13% of cases, respectively (Fig. 1b, right). By immunohis-
tochemistry (IHC) analysis, in the same cohort of patients
(Fig. 1c; Supplementary Fig. 1A), there was correspondence
between EPN3 amplification and overexpression in almost all
cases (Fig. 1d). Furthermore, in more than one-third of cases,
EPN3 was overexpressed in the absence of amplification (Fig. 1d).
Thus, EPN3 is amplified and/or overexpressed in BC, and its
amplification can occur independently of, or concomitantly with,
ERBB2 amplification.
EPN3 overexpression induces partial EMT in MCF10A cells.
Initial experiments in BC cell lines (Supplementary Fig. 2A, B)
revealed that silencing EPN3 reduced tumorigenicity in cells
harboring EPN3 amplification (i.e., BT474, Supplementary
Fig. 2C, D). Conversely, EPN3 ectopic overexpression in not-
amplified/overexpressing BC cells (i.e., HCC1569) increased their
in vivo tumorigenic potential (Supplementary Fig. 2E), arguing
that EPN3 overexpression might be an advantage-conferring
event in BC. Thus, we investigated the mechanisms through
which EPN3 overexpression contributes to tumorigenesis.
The nontumorigenic mammary epithelial cell line, MCF10A,
displays low EPN3 levels and no alterations of its locus
(Supplementary Fig. 2A, B)14. In these cells, we overexpressed
EPN3 at levels comparable with those present in the EPN3-
amplified BT474 cell line (Fig. 2a). Overexpression of EPN3, but
not of the related EPN1 (used as a control), induced a
morphology reminiscent of EMT (Fig. 2b) and resembling that
induced by the known EMT inducer, TWIST (Fig. 2b; Supple-
mentary Fig. 3A)15. When EMT markers were analyzed by
immunoblot (IB), MCF10A-EPN3 showed increased levels of
NCAD (N-cadherin) and VIM (Vimentin), and a modest
decrease of ECAD (E-cadherin) vs. MCF10A-control (Ctr) or
MCF10A-EPN1 (Fig. 2c). While the increase in NCAD and VIM
was paralleled by increased transcription, the decrease in ECAD
did not appear to involve a transcriptional mechanism, at
variance with MCF10A-TWIST (Fig. 2d). EPN3 also induced
increased mRNA levels of fibronectin (FN1) and of the EMT
master regulators, ZEB1, SNAIL and TWIST (Supplementary
Fig. 3B). Finally, MCF10A-EPN3 displayed increased invasiveness
in vitro (Fig. 2e). Thus, the EPN3-induced EMT program
resembles the so-called partial EMT state, a metastable/plastic
state characterized by the concomitant expression of both
epithelial and mesenchymal markers6.
When grown in 3D Matrigel, MCF10A-Ctr formed polarized,
acini-like spheroids recapitulating aspects of glandular architec-
ture in vivo, including the formation of a hollow lumen, apico-
basal polarization, and the deposition of basement membrane
components16. MCF10A-EPN3, similarly to MCF10A-TWIST,
displayed aberrant morphogenesis, with around 40% of organoids
failing to complete the differentiation program (Supplementary
Fig. 3C), while the remaining ones were aberrant (Fig. 2f;
Supplementary Fig. 3D) with multilobular, filled acini of irregular
shape, displaying defects in cell polarization and in the polarized
deposition of basement membrane (Fig. 2g).
EPN3 induces an invasive phenotype in primary organoids. To
investigate the 3D morphogenesis alterations induced by EPN3 in
a more physiological setting, we derived organoids from the
mammary epithelium of conditional EPN3 knock-in (EPN3-KI)
mice, in which the expression of human EPN3 under a strong
promoter can be induced by treatment of cells with CRE
recombinase (see “Methods”). These organoids, in absence of
CRE treatment, closely resembled the in vivo mammary bilayered
acini structures, as they contained both luminal (keratin 8, K8-
positive) and myoepithelial (keratin 5, K5-positive, Supplemen-
tary Fig. 3E) cells. Upon treatment of the organoids with CRE
ex vivo, they lost their confined organization and became invasive
(Fig. 3a), with many cells delaminating from the organoid core
and invading the surrounding Matrigel (Fig. 3a, b). Of note, these
EPN3-positive invading cells displayed significant loss of their
epithelial identity (i.e. they were negative for K5 and K8) and
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16836-y
2 NATURE COMMUNICATIONS |         (2020) 11:3020 | https://doi.org/10.1038/s41467-020-16836-y | www.nature.com/naturecommunications
showed signs of EMT, with decrease of ECAD expression and
acquisition of NCAD staining (Fig. 3b).
EPN3 drives EMT by stimulating ECAD internalization. The
effects of EPN3 overexpression on ECAD were variable across
experiments (compare for instance Figs. 2c, 4f, 5d, 6c, 8g), yet
significant (quantification analysis in Fig. 2c and Supplementary
Fig. 8C). Furthermore, there was no effect on ECAD mRNA
(Fig. 2d). However, changes in ECAD localization or turnover
were shown to be critical in inducing partial EMT
phenotypes17,18. Thus, we analyzed ECAD at cell–cell junctions.
In MCF10A-Ctr and MCF10A-EPN1, ECAD staining was uni-
form in the contact regions (Fig. 4a; Supplementary Fig. 4A). In
MCF10A-EPN3, ECAD signal was lost in a fraction of the cells
(Fig. 4a, b). In agreement with what we observed for total ECAD
levels, the fraction of cells that lost ECAD expression at the
plasma membrane (PM) was variable across experiments (com-
pare standard deviations in Supplementary Fig. 4B right and
Fig. 2c), suggesting that cells are in a metastable state in 2D
culture, possibly depending on cell confluency and plating con-
ditions. More importantly, in cells that retained ECAD expres-
sion, there were marked alterations of the staining pattern, with
the formation of comb-like structures with many radially oriented
strands (Fig. 4a). While this phenotype has previously been
associated with a pre-EMT state19, it was also markedly different
from that in MCF10A-TWIST, in which ECAD staining
was evidently decreased (compatible with its transcriptional
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Fig. 1 Amplification/overexpression of EPN3 in human BCs. a Schematic representation of human chromosome 17. b Venn diagram of EPN3 and ERBB2
amplification in different BC cohorts: BC METABRIC cohort (N= 2137, available at http://www.cbioportal.org)71,72, TCGA invasive BC cohort (N= 1080,
TCGA Research Network: http://cancergenome.nih.gov/), and the IEO cohort (N= 219). Percentage (%) of amplification is shown in parentheses. In the
IEO cohort, EPN3 and ERBB2 were considered amplified when the EPN3/CEP17 ratio was >2.5, and the ERBB2/CEP17 ratio was ≥2.060, respectively. P,
P value of the association between the indicated variables by two-sided Fisher’s exact test. c Representative images of EPN3 IHC (quantification scores are
indicated). Top, images at 20× (bar, 200 μm); bottom, magnification of the boxed insets (bar, 200 μm). d Venn diagram representation of EPN3
amplification (FISH) and overexpression (IHC; score >1.0) in the IEO cohort (N= 212). P, P value of the association between the indicated variables by two-
sided Fisher’s exact test. Source data are provided as a Source Data file.
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downregulation, Fig. 2d and Supplementary Fig. 4B), but the
residual staining appeared morphologically normal (Supplemen-
tary Fig. 4A). Also in this case, EPN1 did not phenocopy EPN3
(Supplementary Fig. 4A, B).
These findings suggested that EPN3 overexpression might alter
the correct assembly of ECAD at cell–cell contacts. This could be
due to altered ECAD endocytosis/trafficking: a process of
established relevance in the assembly of adherens junctions and
in the establishment of EMT20. Indeed, the kinetics of ECAD
internalization was significantly accelerated in MCF10A-EPN3 vs.
MCF10A-Ctr cells (Fig. 4c; Supplementary Fig. 4C). EPN3 did
not have a general role on endocytosis of other PM receptors
(Supplementary Fig. 5A–D), suggesting some degree of
specificity.
EPN3 belongs to the epsin family of adaptors that link
PM proteins with the endocytic machinery21. They also possess
lipid-binding and membrane-bending ability21, and they have been
involved in multiple internalization mechanisms, including
clathrin-mediated and clathrin-independent mechanisms22–24. Both
endogenous and overexpressed EPN3 co-immunoprecipitated
with components of the ECAD adherens junctions: p120-catenin,
β-catenin, and ECAD itself (Fig. 4d). In addition, EPN3
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Fig. 2 EPN3 overexpression induces EMT in MCF10A cells. aMCF10A cells expressing Flag-EPN3 (EPN3) or Flag-EPN1 (EPN1) or empty vector (Ctr), and
IB with the indicated Ab. GAPDH, loading control. BT474 cells: positive control for EPN3 overexpression. Left, MW markers. b Phase-contrast microscopy
of MCF10A cells as in (a), compared with MCF10A-TWIST. Bar, 50 μm. c, d Expression of EMT markers, in the indicated cell lines, by IB (c) or RT-qPCR
(d). In (c, top), GAPDH, loading control. Left, MW markers. In (c, bottom), quantification of ECAD protein levels, normalized on GAPDH expression, is
reported as relative fold change compared with Ctr cells. Results are the mean ± S.D. (n≥ 3). P values (Each Pair Student’s t test, two-tailed) are vs. Ctr,
unless differently indicated; *, <0.05; **, <0.01; ***, <0.001; ns, not significant (here and in all other figures). In (d), the data were normalized on the
average expression of the housekeeping genes 18S-ACTB-GAPDH, and reported as relative fold change compared with Ctr cells (mean ± S.D., n≥ 4); unless
otherwise indicated, the same normalization procedure was used in all figures. e Matrigel invasion assay of the indicated cells (24 h). Top, representative
images (Bar, 400 μm); bottom, invasion index (mean number of invading cells/field over the control) ± S.D. (at least four fields of view were counted/
sample, each in two independent experiments). P value, Student’s t test two-tailed. fMorphogenetic Matrigel assay. Top, representative bright-field images
at low (bar, 1000 μm) and high magnification (bar, 400 μm) of acini grown in Matrigel. Bottom, ratio between regular vs. irregular/multilobular acini.
Results are reported as mean ± S.D. (n= 3 for Ctr and EPN3; n= 2 for TWIST; at least 75 organoids/experiment were counted); acini >50 μm were
analyzed for their circularity (regular, circularity >0.8; irregular, circularity <0.8). P value, Fisher’s exact t test two-sided for 2 × 2 contingency table. g Acini
as in (f), were subjected to IF with the indicated Ab. Blue, DAPI. Two representative images for each sample are shown. Arrows indicate altered basement
membrane deposition. Bar, 200 μm. Source data are provided as a Source Data file.
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co-immunoprecipitated with clathrin (Fig. 4d). Since ECAD
showed some nonspecific binding to control IgGs, we further
confirmed the ECAD–EPN3 interaction by in situ proximity
ligation assay (PLA) (Supplementary Fig. 5E). These results are
compatible with the possibility that EPN3 functions as an endocytic
adaptor recruiting the cargo (i.e., ECAD) for internalization. More
work will be required, however, to characterize the internalization
mechanism of ECAD in these settings.
ECAD loss or its destabilization at cell-to-cell junctions causes
the detachment of active (dephosphorylated) β-catenin from the
junctions and its nuclear translocation, leading to β-catenin
interaction with members of the T cell-specific transcription
factor (TCF) family and to the transcriptional activation of EMT
genes25,26. EPN3-induced ECAD endocytosis correlated with
increased nuclear accumulation of active β-catenin in MCF10A-
EPN3 vs. MCF10A cells (Fig. 4e). Knockdown (KD) of TCF4, a
key downstream nuclear β-catenin interactor27, in MCF10A-
EPN3 reverted the EPN3-induced expression of the two EMT
targets, VIM and NCAD (Fig. 4f, left). This correlated with the
reversion of the elongated, spindle-like, morphology typical of
MCF10A-EPN3 (Fig. 4f, right). These results argue that EPN3
overexpression causes destabilization of cell–cell junctions
through increased ECAD internalization, followed by β-catenin
nuclear translocation and TCF4-dependent upregulation of EMT
target genes.
EPN3 overexpression potentiates TGFβ signaling. Since the
overexpression of EPN3 induces a partial EMT state, arguably
through augmented ECAD endocytosis, we investigated whether
it might synergize with one of the major inducers of EMT and of
ECAD endocytosis, the TGFβ pathway28–30. The kinetics of
TGFβ-induced ECAD internalization was significantly acceler-
ated in MCF10A-EPN3 vs. MCF10A-Ctr cells (Fig. 5a, b). In
addition, EPN3 and ECAD were co-trafficked in the same
endocytic structures upon TGFβ stimulation (Fig. 5c), and their
interaction by PLA was increased by TGFβ treatment, further
supporting their physical interaction (Supplementary Fig. 5E).
We investigated whether EPN3 overexpression cooperates with
the TGFβ also in the establishment of EMT phenotypes. We
stimulated MCF10A-Ctr and MCF10A-EPN3 with TGFβ at two
concentrations (a low suboptimal dose, 0.75 ng ml−1, and a high
dose, 5 ng ml−1) and analyzed early (i.e., SNAIL expression) and
delayed (i.e., ECAD, NCAD, VIM and ZEB1 levels) transcrip-
tional responses. In EPN3-overexpressing cells, there was
sustained activation of TGFβ signaling at both TGFβ doses, as
evidenced by: (i) sustained induction of the transcription factor
SNAIL (Fig. 4d, top), (ii) increased basal levels of NCAD and
VIM expression both by IB and RT-qPCR analysis, which were
further enhanced by TGFβ stimulation (Fig. 5d, top and bottom;
Supplementary Fig. 5F, top left), (iii) increased (basal) and
sustained (upon stimulation) expression of the late TGFβ-
induced transcription factor ZEB1 (Supplementary Fig. 5F, top
right) and of FN1 (Supplementary Fig. 5F, bottom left), iv)
decreased ECAD protein levels (basal and upon stimulation,
Fig. 4d, top). Notably, long-term stimulation (14 days) with TGFβ
was able to reduce ECAD levels also at the transcriptional level in
MCF10A-EPN3 but not in control cells (Supplementary Fig. 5F,
bottom right). Thus, EPN3 overexpression enhances and sustains
TGFβ-dependent signaling and transcriptional programs leading
to an EMT state, and possibly connected with the acquisition of
aggressive phenotypes. Indeed, the combination of suboptimal
TGFβ stimulation (incapable of stimulating invasion in control
cells) and EPN3 overexpression further enhanced the invasive
potential of MCF10A-EPN3 cells in the Matrigel invasion assay
(Fig. 5e).
Notably, we confirmed the partial EMT phenotype induced by
EPN3 overexpression in a nontumorigenic mammary epithelial
cell line of different derivation compared to MCF10A, i.e.
MCF12A, and in the non-overexpressing BC cell line HCC1569
(Supplementary Figs. 6 and 7).
Finally, the silencing of endogenous EPN3 in MCF10A reduced
both ECAD internalization and transcriptional activation of
NCAD and VIM induced by high doses of TGFβ stimulation
(Fig. 5f, g), suggesting that EPN3 sustains TGFβ-induced EMT
also under physiological conditions, possibly by modulating
ECAD endocytosis. These results argue that the effects of EPN3
overexpression represent an exaggeration of its physiological
function.
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EPN3-driven partial EMT is due to a TGFβ autocrine loop.
Since EPN3 overexpression renders the cell more responsive to
TGFβ, we investigated whether the endogenous TGFβ signaling
pathway plays a role in the EPN3-induced partial EMT state. In
EPN3-overexpressing cells, the transcript levels of TGFβ ligand 1
(TGFβ1), ligand 2 (TGFβ2), and receptor 2 (TGFβR2) were sig-
nificantly increased vs. control cells (Fig. 6a). Moreover, increased
TGFβ1 was detected in the supernatant of EPN3-overexpressing
cells vs. MCF10A (Fig. 6b) or MCF10A-EPN1 cells (Supple-
mentary Fig. 8A). This suggested the existence of a transcriptional
positive feedback, leading to the creation of a TGFβ-dependent
autocrine loop, required to sustain the partial EMT phenotype in
EPN3-overexpressing cells. To test this possibility, we silenced
TGFβ receptors (type 1 and 2, individually or in combination) in
MCF10A-EPN3 cells (Fig. 6c; Supplementary Fig. 8B) and
observed reversion of EMT evidenced by: (i) reduction in NCAD
and VIM proteins (Fig. 6c, top; Supplementary Figs. 8B, right and
8C) and mRNA levels of TGFβ1, NCAD and VIM (Fig. 6d; see
also Supplementary Fig. 8D), and (ii) reversion of the fibroblast-
like morphology toward an epithelioid one (Fig. 6c, bottom).
EPN3 overexpression and TGFβ stimulation acted synergistically
not only on NCAD and VIM mRNA levels but also on TGFβ1
mRNA (Fig. 6d), reinforcing the notion of the existence of
a feedback loop that acts on EMT and on TGFβ signaling
itself. These results were confirmed using a chemical inhibitor of
the kinase activity of TGFβR1-2, LY2109761, which was able
to revert the EPN3-dependent phenotypes (Supplementary
Fig. 9A, B)31.
The EMT reversion upon TGFβR1 ablation and LY2109761
treatment was comparable with that achieved by silencing TCF4
(Fig. 6c, d), which could also act downstream of TGFβ
signaling32. Consistently, the EMT reversion upon TCF4 KD
was observable in MCF10A-EPN3 cells both in basal and TGFβ-
stimulated conditions (Fig. 6d). This result shows that the EPN3-
induced autocrine TGFβ-based loop is TCF4-dependent.
Finally, we note that the reversion of EPN3-induced partial
EMT upon TGFβR KD, TCF4 KD, or LY2109761 treatment was
not complete. Although we cannot exclude that this is due to
incomplete KD or inhibition, these data seem to argue that EPN3-
induced partial EMT is—to some extent—also independent of
TGFβ signaling and/or TCF4 activity, an issue that will require
further investigations.
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Fig. 4 EPN3 stimulates ECAD internalization and β-catenin/TCF4-dependent EMT. a IF staining of ECAD (green) in the indicated cells, at confluency.
Blue, DAPI. Asterisks, cells lacking ECAD staining. Bar, 10 μm. b Representative FACS analysis of the indicated cells stained in vivo for ECAD. Black and red
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percentage of ECAD-positive cells ± S.D. (n= 18) is reported. P value, Student’s t test two-tailed. See also Supplementary Fig. 4B. c Time course of ECAD
internalization in the indicated cells measured by FACS analysis. Fraction of mean fluorescence intensity of internalized ECAD signal over the total ± S.D.
(n≥ 3) is reported. Student’s t test, two-tailed. d Lysates (1 mg) from the indicated cells were subjected to immunoprecipitation with anti-EPN3 Ab or with
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markers. Results are representative of at least two independent experiments. e Left, representative confocal images of the indicated cells stained for active
β-catenin. Blue, DAPI. Bar, 30 µm. Right, box plot analyses of relative nuclear fluorescence intensity of active β-catenin per cell in MCF10A-Ctr (N= 34)
and MCF10A-EPN3 cells (N= 36) in a representative experiment (n= 3). Data were normalized on the median value of nuclear fluorescence intensity in
MCF10A-Ctr. P value, each pair, Student’s t test, two-tailed. f TCF4 was silenced in the indicated cells. Negative control, mock transfection. Left, cell lysates
were IB with the indicated Ab. GAPDH, loading control. Left, MW markers. See Supplementary Fig. 8C for quantitation and statistics. Right, representative
phase-contrast microscopy of mock or TCF4-KD MCF10A-EPN3 cells. Bar, 250 µm. Source data are provided as a Source Data file.
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ECAD endocytosis is the first event in EPN3-driven EMT.
Together, our data suggest a scenario in which accelerated ECAD
endocytosis, induced by EPN3 overexpression, activates the β-
catenin/TCF4-dependent EMT program, as well as a TGFβ-
dependent loop that positively feedbacks on ECAD endocytosis,
on TCF4-dependent EMT and on TGFβ signaling itself, thereby
establishing the partial EMT phenotype and the invasive prop-
erties of the cells (Fig. 6e).
To challenge this model and, in particular, to test whether
ECAD endocytosis is the initial event in EPN3-driven partial
EMT, we generated a doxycycline-inducible EPN3 overexpression
system in MCF10A cells (Fig. 7a). This system allowed us to
define the temporal order of the events. At 6 h after induction, we
observed a slight change in cell morphology, which became more
dramatic after 24 h (Fig. 7b). Importantly, TGFβ ligands and
receptors, as well as other EMT factors, were not yet upregulated
at 6 h of induction (Fig. 7c; Supplementary Fig. 9C). Despite the
lack of TGFβ pathway activation, ECAD endocytosis was
accelerated (Fig. 7d, e), cell-to-cell junctions were rearranged
(Fig. 7d) and active β-catenin was translocated to the nucleus
(Fig. 7f). These results demonstrate that these events occur before
the establishment of the TGFβ-dependent loop and most likely
represent the first steps of EPN3-induced partial EMT.
Notably, once the loop is established, the β-catenin/
TCF4 system likely cooperates with TGFβ signaling, as supported
by the evidence that the TGFβ-dependent transcriptional events
are also in part dependent on β-catenin/TCF4 (Fig. 6d;
Supplementary Fig. 8D).
Finally, by taking advantage of the inducible system, we could
recapitulate some of the EPN3-dependent phenotypes also in
MCF10A-derived organoids grown in 3D Matrigel where, by
inducing the overexpression of EPN3 at the end of the
morphogenesis process, we observed rearrangements of ECAD
cell-to-cell junctions and the translocation of active β-catenin into
the nucleus (Fig. 7g).
EPN3 overexpression causes the appearance of CSC traits. EMT
has been linked to the emergence of CSCs4. We searched for the
appearance of CSC traits in EPN3-overexpressing cells by
exploiting the CD44high/CD24low configuration, which has been
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Fig. 5 EPN3 is involved in TGFβ-induced ECAD internalization and TGFβ signaling. a Left, ECAD internalization assay by IF in the indicated cells using an
anti-ECAD Ab against the extracellular domain internalized for 30min −/+ TGFβ (5 ng ml−1). Cells were subjected or not to an acid wash (AW) to
remove the ECAD Ab from the PM, prior fixation. Bar, 20 µm. Right, box plot of relative ECAD fluorescence intensity/field of view (N≥ 9). P value, each
pair Student’s t test two-tailed. b ECAD internalization assay by FACS in the indicated cells, −/+ TGFβ1 (5 ng ml−1, 30min). Mean fluorescence intensity
of internalized ECAD/total ± S.D. (n≥ 4) is reported. P value, Student’s t test two-tailed. c Representative co-localization images of EPN3 (red) and ECAD
(green), during ECAD internalization as in (a). Bars, 10 µm. d Top, lysates from the indicated cells −/+ TGFβ1 (0.75 or 5 ngml−1, for the indicated days—d)
were IB with the indicated Ab. β-actin, loading control. Right, MW markers. Bottom, NCAD mRNA levels by RT-qPCR on samples −/+ TGFβ1 (5 ngml−1).
Mean relative mRNA expression vs. MCF10A-Ctr (not stimulated) ± S.D. (two independent experiments, each in technical triplicates) is reported. P value, each
pair Student’s t test, two-tailed. Black asterisks, statistical significance between each corresponding time point of EPN3 vs. Ctr; red asterisks, statistical
significance between stimulated vs. not stimulated samples of MCF10A-EPN3 or -Ctr cells. eMatrigel invasion assay of the indicated cells −/+ TGFβ (0.75 ng
ml−1). Top, invasion index (mean number of invading cells/field vs. control) ± S.D. (N≥ 22). P value, Student’s t test two-tailed. Bottom, representative images.
Bar, 50 µm. f ECAD internalization assay by FACS analysis in MCF10A-Ctr −/+ EPN3 silencing, −/+ TGFβ1 (5 ngml−1, 180min). Mean fluorescence intensity
of internalized ECAD/total ± S.D. (n≥ 5) is reported. P value, Student’s t test two-tailed. g RT-qPCR analysis of NCAD and VIM mRNA levels in cells as in (f).
Mean relative mRNA expression vs. mock-unstimulated cells ± S.D. (n≥ 4) is reported. P value, each pair Student’s t test, two-tailed. Source data are provided
as a Source Data file.
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associated with EMT and human mammary CSCs4,33. MCF10A-
Ctr or -EPN1 cells displayed a very small percentage of these cells
(0.1% and 0.4%, respectively); conversely MCF10A-EPN3 or
-TWIST cells contained ∼7% and 30% of this subpopulation,
respectively (Fig. 8a, b; Supplementary Fig. 10A).
At the biological level, we employed the mammosphere (MS)
assay, which can be utilized (with due caution) as a proxy for the
detection of cells with stem-like properties34,35 In this assay,
MCF10A-EPN3, similarly to MCF10A-TWIST, displayed a
sphere-forming efficiency (SFE) at least tenfold higher than
control or EPN1-overexpressing cells (Fig. 8c). The increase in
SFE in MCF10A-EPN3 vs. -Ctr (or -EPN1) significantly
correlated with the increase in the CD44high/CD24low population
(compare Fig. 8c, b). In agreement, the MS-forming ability
resided almost exclusively in the CD44high/CD24low subpopula-
tion (Fig. 8d), which is also the subpopulation displaying EMT
traits, as confirmed by the expression pattern of EMT-specific
markers (Fig. 8e).
Finally, the percentage of CD44high/CD24low CSC-like cells in
MCF10A-EPN3 (or MCF10A-TWIST) was considerably reduced
by TGFβR1 KD (Fig. 8f), which correlated with reversion of EMT
(Fig. 8g).
The transition from in situ to invasive BC involves EPN3.
Augmented invasiveness in vivo is connected with the acquisition
of EMT traits and CSC-like properties4,5. To investigate this
possibility, we took advantage of the human BC cell line
MCF10DCIS.com, a derivative of MCF10A cells, which repro-
ducibly forms comedo DCIS (ductal carcinoma in situ)-like
lesions that spontaneously progress to invasive tumors in xeno-
graft models36.
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Fig. 6 EPN3-driven partial EMT relies on a TGFβ-based autocrine loop. a RT-qPCR analysis of mRNA expression of TGFβ ligands (TGFβ1, TGFβ2) and
receptors (TGFβR1, TGFβR2) in MCF10A-Ctr and -EPN3 cells. Mean relative mRNA expression compared with MCF10A-Ctr ± S.D. of nine independent
experiments, each performed in technical triplicates. P value, Student’s t test two-tailed. b ELISA assay of secreted TGFβ1 in conditioned media from
MCF10A-Ctr and -EPN3 cell cultures. Results are reported as pgml−1 10−6 cells ± S.D. (n= 3, each performed on the medium of at least two independent
dishes, each assayed in technical triplicates). P value, Student’s t test two-tailed. The same data are also reported in Supplementary Fig. 8A top for
comparison between MCF10A-Ctr, -EPN3, -EPN1, and -TWIST. c Top, TCF4 or TGFβR1 were silenced in the indicated cells. Mock transfection was used as
negative control. Cell lysates were IB with the indicated Ab. This panel was assembled from samples run on the same gel by splicing out the irrelevant lanes
(as shown by the black lines). GAPDH, loading control. Right, MW markers. Relative protein levels of NCAD, ECAD and VIM of this blot were quantified
together with other experiments (see Supplementary Fig. 8C for quantitation and statistics). Bottom, representative phase-contrast microscopy of
MCF10A-EPN3 cells, mock, TCF4 KD or TGFβR1 KD. Bar, 250 µm. d RT-qPCR analysis of mRNA expression of the indicated genes in MCF10A-Ctr and
-EPN3 cells that were mock-treated or subjected to TGFβR1 KD or TCF4 KD, and stimulated or not with TGFβ1 (5 ngml−1, 48 h). Results are reported as
relative mRNA expression compared with the MCF10A-Ctr mock-treated sample, mean ± S.D. (n≥ 3, each performed in technical triplicates). P value, each
pair Student’s t test, two-tailed. Black asterisks, statistical significance between KD samples vs. mock, not treated, and KD samples vs. mock, treated with
TGFβ1, as indicated by the bar; red asterisks, statistical significance between matched MCF10A-EPN3 samples vs. -Ctr samples. e Proposed model of the
EPN3-dependent activation of the EMT program in mammary epithelial cells. Source data are provided as a Source Data file.
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Fig. 7 ECAD accelerated endocytosis is the initial event in EPN3-driven EMT. a MCF10A-Ctr cells were infected with pSLIK-empty vector (Ctrdox) or
pSLIK-EPN3 (EPN3dox) and treated for 6 h or 24 h with 200 μg ml−1 doxycycline (dox). Lysates were subjected to IB analysis with the indicated Ab.
GAPDH, loading controls. Lysates of MCF10A-Ctr and MCF10A-EPN3 were loaded in parallel as controls. Right, MW markers. b Phase-contrast
microscopy of cells as in (a). Bar, 60 μm. c RT-qPCR analysis of mRNA expression of the indicated genes in cells as in (a). Mean relative mRNA expression
compared with MCF10A-Ctr, ± S.D. is reported (n= 3, each performed in technical triplicates). P value, each pair Student’s t test, two-tailed. d IF staining of
ECAD (green) in cells (a). Blue, DAPI. Bar, 20 μm. e Time course of ECAD internalization measured by FACS analysis in MCF10A-Ctrdox and -EPN3dox cells
treated with dox for 6 h. Data are reported as fraction of mean fluorescence intensity of internalized ECAD signal over the total, ± S.D. (n= 3). P values,
Student’s t test two-tailed. f Left, representative confocal images of the indicated cells dox-induced for 6 h and 24 h, and stained for active β-catenin. Blue,
DAPI. Bar, 20 µm. Right, box plot analyses of relative nuclear fluorescence intensity of active β-catenin per cell in MCF10A-Ctrdox 6 h (N= 222), MCF10A-
Ctrdox 24 h (N= 323), MCF10A-EPN3dox 6 h (N= 98) and MCF10A- EPN3dox 24 h cells (N= 144) in a representative experiment (n= 3). Data were
normalized on the median value of nuclear fluorescence intensity in the MCF10A-Ctrdox 6 h sample. P value, each pair Student’s t test, two-tailed. g Left,
acini grown in 3D on top of Matrigel for 13 days were treated for 24 h with doxycycline and then subjected to IF with the indicated Ab. Blue, DAPI. Bar,
20 μm. Right, box plot of relative nuclear fluorescence intensity of active β-catenin per cell in a representative experiments of two independent replicates.
Data were normalized on the median value of nuclear fluorescence intensity in the MCF10A-Ctrdox 24 h sample. MCF10A- Ctrdox (N= 86) and MCF10A-
EPN3dox cells (N= 91). P value, each pair Student’s t test two-tailed. Source data are provided as a Source Data file.
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By analyzing the expression levels of ECAD, VIM, and NCAD,
we showed that MCF10DCIS.com cells, grown in 2D, exhibited
some traits of EMT, as indicated by the expression of NCAD and
VIM (Fig. 9a). The KD of EPN3 caused a partial reversion of this
EMT phenotype in 2D culture conditions, as witnessed by a
decrease in VIM expression and slight upregulation of ECAD
(Fig. 9a). When engrafted into the mammary fat pad, tumors
formed by parental MCF10DCIS.com recapitulated the progres-
sion of DCIS into invasive BC (IBC), as confirmed by IHC
analysis using the basal-myoepithelial marker p63 (Fig. 9b), that
has been shown to increase during the progression from DCIS to
IBC36. Moreover, in DCIS, p63 marked the myoepithelial cell
layer, while in IBC the majority of infiltrating cells became p63-
positive, accompanied by a concomitant increase in α-SMA-
positive fibroblasts in the stroma associated with IBC, as
previously reported (Fig. 9b, c)36. In addition, cells in the invasive
area lost the epithelial marker ECAD and acquired the
mesenchymal marker NCAD, thus recapitulating EMT in vivo
(Fig. 9c, red arrowheads). Concomitantly, endogenous EPN3
levels were significantly increased in the infiltrating areas (Fig. 9c,
d, red vs. black arrowheads), suggesting a possible role of EPN3 in
the progression from in situ to IBC. Indeed, EPN3 silencing in
MCF10DCIS.com cells not only reduced tumor growth (Supple-
mentary Fig. 10B), but importantly, also reduced the p63/α-SMA-
positive area of tumors during IBC progression over time, when
normalized on tumor size (Fig. 9e, f).
These data indicate that, in the in vivo 3D context, the effects
of EPN3 silencing are more pronounced than in 2D (Fig. 9a),
causing a decrease in the infiltrating tumor areas that have
undergone EMT in vivo (Fig. 9f; Supplementary Fig. 10C). Thus,
EPN3 upregulation participates to the progression from in situ to
invasive BC.
High EPN3 level is an independent predictor of BC metastasis.
To investigate the relevance of this finding to human BCs, we
selected a subset of human primary BCs (N= 50), in which we
could detect both DCIS and IBC areas in the same slide. EPN3
levels were upregulated in the infiltrating area adjacent to the
in situ component in ~20% of these samples (11 out of 50,
Fig. 10a, b, red dots), showing that EPN3 endogenous levels are
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upregulated in a fraction of human BCs that are undergoing the
in situ to invasive transition.
Given the link between EPN3 and the invasive behavior of
cancer cells, we aimed to establish the clinical relevance of EPN3
to BC metastasis. By analyzing EPN3 expression (IHC or RT-
qPCR) in a large retrospective consecutive cohort (IEO BC 97-00)
of ~2400 BCs (Supplementary Tables 1–2)14, we determined that
high EPN3 expression was an independent predictor of poor
prognosis, in multivariable analysis, associated with a higher risk
of distant metastasis (Fig. 10c; Supplementary Table 3). The
prognostic value of a high EPN3 status was linked to the
metastatic phenotype per se, as no correlations were found with
loco-regional disease recurrence (Fig. 10c; Supplementary
Table 3). Importantly, EPN3 overexpression was an independent
predictor of unfavorable outcome in node-negative patients
(by RT-qPCR) and in the subgroup of ERBB2-negative
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patients (by RT-qPCR and IHC, Fig. 10d; Supplementary
Table 3).
Discussion
We herein demonstrate that EPN3 is a bona fide oncogene in BC,
as supported by: (i) genetic alterations of the EPN3 locus; (ii) high
frequency of EPN3 overexpression, in the presence or absence of
gene amplification; (iii) its ability to independently predict
metastasis; (iv) the attenuation upon EPN3-KD, and the increase
upon EPN3 overexpression, of in vivo tumorigenicity of BC cell
lines harboring or not EPN3 gene amplification, respectively; (v)
the induction of EMT, and the appearance of cells with traits of
CSCs, upon EPN3 overexpression in model systems in vitro; (vi)
the invasive phenotype induced by EPN3 overexpression in
ex vivo primary mammary organoids; (vii) the upregulation of
EPN3 at the leading edge of infiltrating human BCs; (viii) the
attenuation upon EPN3-KD of the transition from in situ to
invasive carcinomas in vivo.
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At the genetic level, EPN3 is situated in a region on the long
arm of Ch. 17, roughly 10.8 Mbp apart from the ERBB2 gene,
which is also frequently amplified/overexpressed in BC37,38. The
two alterations, however, seem to influence the tumor phenotype
independently, as supported by finding that ~50% of the EPN3-
amplified cases do not show ERBB2 amplification. In addition,
the major alteration of EPN3 is represented by overexpression
without gene amplification, at a frequency (30–40%) that exceeds
that of ERBB2 amplification (~18–20%)38,39. Consistently, EPN3
overexpression stratified poor prognosis BCs even in the ERBB2-
negative subset. It is interesting, however, that in around one
quarter of all ERBB2-amplified cases, there is concomitant
amplification of EPN3. The co-occurrence of alterations becomes
even more evident if one considers EPN3 overexpression
(regardless of amplification) and ERBB2-positivity. In this case,
the frequency climbs to almost two thirds of all ERBB2-positive
cases. Thus, the cooperation between ERBB2 and EPN3 in BC
biology appears worthy of future investigations, also in light of
the possibility that EPN3 status might modify the response to
anti-ERBB2 therapies40. Furthermore, EPN3 overexpression
stratified poor outcome patients also in the BC node-negative
category. Since recommendations for adjuvant therapy in this
category of patients is not as straightforward as in the node-
positive subgroup, the identification of EPN3 as an independent
risk marker might aid in the development of more precise criteria
for the eligibility for therapy in node-negative patients.
At the biological level, EPN3 contributes to mammary
tumorigenesis likely through the induction of a partial EMT
phenotype, characterized by the simultaneous presence of epi-
thelial and mesenchymal markers5,6,17,18,41–43. Indeed, when
compared with a potent inducer of EMT, TWIST, EPN3-
overexpressing cells displayed a milder EMT phenotype, char-
acterized by a less pronounced upregulation of the EMT tran-
scription factors ZEB1 and TWIST, and not resulting in the
transcriptional repression of ECAD, which was—however—
regulated at the post-transcriptional level. The hypothesis that the
EPN3-induced phenotype represents a partial EMT is also sup-
ported by the synergy of EPN3 and TGFβ towards a more
advanced EMT state.
Interestingly, cells in a partial EMT state display the highest
level of plasticity, i.e., the ability to switch between invasive/
mesenchymal and proliferative/epithelial modes, when com-
pared with cells that have undergone full EMT. Therefore, it has
been proposed that cells harboring partial EMT are more prone
to metastasize to distant organs43. This behavior correlates well
with the clinical impact of EPN3 overexpression in the natural
history of BC, which is exerted at the level of the metastatic
phenotype rather than on local expansion and aggressiveness,
as shown by the lack of correlation with loco-regional
recurrence.
At the mechanistic level, one physiological function of EPN3,
uncovered in our study, is to participate to ECAD internalization,
in line with the general endocytic role attributed to epsins.
However, there seems to be specificity in EPN3 molecular
workings, as its perturbation did not affect the internalization of
selected PM cargoes. In turn, this might be consistent with the
restricted physiological pattern of EPN3 expression and its
selective activation when the migratory phenotype is required8, a
condition in which loss of ECAD-mediated cell–cell contacts
would be desirable. EPN3 overexpression resulted in an exag-
geration of this physiological function, leading to increased
ECAD internalization.
Data obtained with an inducible EPN3 overexpression sys-
tem support the possibility that stimulation of ECAD endocy-
tosis is indeed the first event in EPN3-driven EMT. This
conclusion is in agreement with extant literature showing that:
(i) at steady state, the slow, but continuous, endocytic uptake
and recycling of ECAD (as herein seen, in unperturbed
MCF10A cells, Fig. 3c) is involved in adherent junction
remodeling44,45, a process that has been shown to be critical in
the establishment of epithelial cell polarity, epithelial cell
division and tissue integrity44,45, (ii) mechanisms that accel-
erate ECAD endocytosis and turnover at the PM are known to
induce EMT and the invasive/metastatic phenotype3, (iii) par-
tial EMT phenotype is linked to the endocytic-dependent re-
localization of epithelial markers, such as ECAD, and not to
their direct transcriptional downregulation17,41,42.
Our data do not allow to establish the mechanism of ECAD
internalization regulated by EPN3. Indeed, although EPN3 binds
to clathrin in MCF10A, this does not implicate that it drives
ECAD endocytosis via clathrin-coated pits. Indeed, Epsins,
despite their strong binding to clathrin and to the clathrin
adaptor AP2, are known to regulate both clathrin-dependent and
-independent mechanisms22–24. Furthermore, there is consider-
able functional redundancy among epsins46,47. While more work
is needed to establish the ECAD internalization route controlled
by EPN3, our data converge on the possibility that this function
might be non-redundant at least vs. EPN1. This, in turn might
have implications for the transforming potential of the various
members of the family, as will be further discussed below.
Downstream of ECAD internalization, we dissected the mole-
cular workings of the EPN3-triggered circuitry and showed that it
is based on the activation of a TGFβ-based autocrine loop
(Fig. 6e). The establishment of TGFβ-dependent auto-regulatory
loops has been previously described as relevant to the induction
of EMT48,49, through the activation of large transcriptional pro-
grams that depend on a number of pathways, including β-cate-
nin-, Wnt-, and RTK-based ones3. Consistent with this, we
showed that, consequent to EPN3-induced ECAD endocytosis,
the β-catenin/TCF4 pathway was directly involved in the
Fig. 10 High EPN3 levels correlate with IBC and independently predict metastasis. a H&E staining and EPN3 IHC images of in situ (DCIS) and adjacent
infiltrating area (IBC) detected in two different primary human BCs. Images at ×20. Bar, 100 µm. b Summary graph of the differential expression of EPN3
detected by IHC in human BC samples in areas of DCIS vs. adjacent IBC. Data are reported as IHC score in IBC relative to DCIS. N, number of tumor
samples. P value, two-sided Wilcoxon signed-rank test. c Cumulative incidence of distant metastasis or loco-regional relapse in BC patients of the IEO
consecutive cohort (IEO BC 97-00, N= 2453), stratified by EPN3 protein (top, IHC) or mRNA (bottom, RT-qPCR) levels. HR*, multivariable hazard ratio.
Multivariable models were adjusted for tumor grade, tumor size, Ki-67 levels, ERBB2 status, ER/PR status, number of positive lymph nodes, and age at
surgery, see Supplementary Table 3. d Forest plot of the multivariable hazard ratios of distant metastasis and 95%Wald confidence intervals (whiskers) in
the entire cohort of patients (All) and in the ERBB2-negative (ERBB2-NEG) or lymph node-negative (pN0) subgroups of patients stratified by EPN3 protein
(IHC) or mRNA (RT-qPCR) expression levels. The size of the solid squares and diamonds is proportional to the number of distant metastases. The number
(N) of patients and distant metastases (DM) in each group is indicated. Hazard ratios were estimated with a Cox proportional hazards multivariable model,
adjusted for Grade, Ki-67, ERBB2 status, estrogen/progesterone receptor status, tumor size (pT), number of positive lymph nodes (pN), and age at surgery
(as appropriate). The number of patients in each subgroup analysis corresponds to those reported in Supplementary Tables 1 and 2 for IHC and RT-qPCR,
respectively. P value, Wald test P value. See also Supplementary Tables 1–314. Source data are provided as a Source Data file.
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acquisition of the transcriptional circuitry necessary to sustain the
partial EMT25,26. Among the distal events, the increased
transcription of TGFβ ligands and receptors is of particular
interest, as they could potentially generate an autocrine loop,
sustaining and reinforcing the EPN3-triggered events, since TGFβ
is in itself an inducer of ECAD endocytosis and of activation of
EMT programs28. This possibility was formally proven by
ablating the expression of TGFβRs, which reverted the EPN3-
induced phenotypes. We acknowledge, however, that the
contribution of other mechanisms is not excluded by our data.
In particular, EPN3 overexpression might inhibit negative
feedback regulators of TGFβ signaling (see, for instance, see
ref. 50). Furthermore, our data are also compatible with the
existence of some EPN3-specific effects, independent of TGFβ
signaling and of TCF4/β-catenin axis, which could act in parallel
with the TGFβ-dependent ones.
Finally, we would like to comment on the oncogenic potential
of the epsin family. While a potential role in regulating tumor
angiogenesis has been proposed for EPN1 and EPN251,52, our
results show that EPN1 overexpression does not phenocopy any
of the investigated EPN3 effects, thereby pointing to a specific
modality of transformation by EPN3, at least in BC. At the
sequence level, EPN3 shows a high degree of similarity with the
other family members. All three members possess binding motifs
for clathrin, AP2, and ubiquitin. The central and the C-terminal
portions of the protein are the most divergent ones. EPN3 dis-
plays a specific sequence, located after the ubiquitin-binding
motifs, encoded by a specific exon (Exon 5) conserved between
human, mouse, and rat, which is not present in EPN1-2. This
region, therefore, is an obvious candidate for the identification of
the molecular determinants of EPN3 specificity. In the future, it
will be of interest to identify the minimal EPN3 region respon-
sible for the effects, with the perspective of developing specific
inhibitors. This, coupled to its restricted pattern of expression in
adult tissues, makes EPN3 an attractive therapeutic target in BC.
Furthermore, the interplay between EPN3- and TGFβ-based
signaling in BC might be of clinical relevance, since several TGFβ
signaling inhibitors are being developed53. EPN3 may, therefore,
represent a predictive biomarker to identify which patients are
most likely to benefit from targeted anti-TGFβ signaling
therapies.
Methods
Description of the retrospective consecutive IEO BC cohort. For the analyses
reported in Fig. 10c, d and Supplementary Tables 1–3, we used a large retrospective
consecutive cohort of 2453 breast cancer (BC) patients operated at the European
Institute of Oncology (IEO), Milan, Italy, between 1997 and 2000 (the IEO BC 97-
00 cohort). Detailed description of the selection criteria and the clinico-
pathological characteristics of this cohort have been reported elsewhere13. Briefly,
available clinical and pathological information included age, date at surgery, tumor
characteristics (histological type, tumor size, nodal involvement, grade, perivascular
infiltration, Ki-67 and ER/PgR expression), and treatment modality (type of sur-
gery, adjuvant radiotherapy, endocrine therapy, chemotherapy). Patients of this
cohort were followed up with physical examination every 6 months, annual
mammography and breast ultrasound, blood tests every 6–12 months, and further
evaluations only in the case of symptoms. When possible, the status of women not
presenting at the institute for scheduled follow-up visits for more than one year was
obtained by telephone contact. Cumulative incidence of Loco-regional (LR) and
distant metastasis (CI-DM) were defined as the time from surgery to the appear-
ance of a local or regional recurrence and distant metastases or death from BC as
first event, respectively54. Second primary cancer or death from unknown causes or
other causes were considered competing events. Considering first events, median
follow-up for censored patients was 14.1 years (interquartile range [IQR]
12.1–15.7). One hundred and eighty-five (7.5%) patients were lost at 10 years of
follow-up. Research on human samples was approved by the IEO Institutional
Review Board.
TMA construction and RNA extraction from the IEO BC cohort. From the IEO
BC 97-00 cohort of 2453 samples (see above), 2275 were appropriate for the
construction of ad hoc tissue microarrays (TMAs): samples with massive
inflammatory infiltration, massive necrosis, minimal areas of infiltrating carcinoma
were discarded. TMAs were prepared as previously described55. Briefly, repre-
sentative tumor areas (three tissue cores of 0.6 mm in diameter) from each sample,
previously identified on hematoxylin and eosin (H&E)-stained sections, were
removed from the paraffin donor blocks and deposited on recipient blocks using a
custom-built precision instrument (Tissue Arrayer - Beecher Instruments, Sun
Prairie, WI 53590, USA).
For the PCR analysis, 2335 tissue blocks were appropriate for RNA extraction,
and one tissue core of 1.5 mm diameter (in close proximity to the tissue core used
for TMA construction whenever possible) or at least two tissue sections (10-μm
thick) were taken from representative tumor areas with adequate tumor cellularity
(>60%) selected by a pathologist for each tissue block. Samples with massive
inflammatory infiltration, massive necrosis, minimal areas of infiltrating carcinoma
were discarded. The total RNA was extracted from formalin-fixed paraffin-
embedded (FFPE) tissues using the AllPrep DNA/RNA FFPE Kit automated on
QIAcube, following the manufacturer’s instructions (Qiagen, Hilden, Germany).
Quantitative real-time PCR analysis of human BCs. For EPN3 mRNA analysis,
250 ng of the total RNA (RNA concentration measured using the NanoDrop® ND-
1000 Spectrophotometer) were reverse transcribed with random primers using the
SuperScript® VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific), pre-amplified
with the PreAMP Master Mix Kit (Thermo Scientific) for ten cycles, following the
manufacturer’s instructions, and diluted 1:25 prior to PCR analysis (5 µl were then
used per PCR reaction, corresponding to 1 ng of cDNA). Quantitative PCR was
performed with hydrolysis probes (Thermo Fisher Scientific) using the SsoAd-
vanced Universal Probes Supermix (Bio-Rad Laboratories) in 10 μl of final volume
in 384-well plates. PCR reaction was run in LightCycler (LC) 480 real-time PCR
instruments (Roche) using the following thermal cycling conditions: 1 cycle at
95 °C for 30 s, 45 cycles at 95 °C for 5 s and 60 °C for 30 s.
TaqMan gene expression assays, with short amplicon sizes, were as follows:
Hs00978957_m1 (EPN3), Hs02800695_m1 (HPRT1), Hs03929097_g1 (GAPDH),
Hs99999908_m1 (GUSB), and Hs00427621_m1 (TBP).
We defined Cq=35 as our limit of detection. Therefore, Cq values beyond this
limit were set to 35, and normalization was omitted. Each target was assayed in
triplicate, and average Cq (AVG Cq) values were calculated either from triplicate
values when the standard deviation was <0.4, or from the best duplicate values
when the standard deviation was ≥0.4. Data (AVG Cq) were normalized using four
reference genes (HPRT1, GAPDH, GUSB, and TBP) to account for variation in the
expression of single-reference genes and in RNA integrity due to tissue fixation.
The normalized Cq (Cqnormalized) of EPN3 target gene was calculated using the
following formula:
Cqnormalized ¼ AVG Cq SF;
where SF is the difference between the AVG Cq value of reference genes for each
patient and a constant reference value K; K represents the mean of the AVG Cq of
the four reference genes calculated across all samples (K= 25.012586069). This
normalization strategy allows the retention of information about the abundance of
the original transcript, as measured by PCR (i.e., in Cq scale), which is conversely
lost when using the more classical ΔCq method. Normalized data were then
processed for statistical analysis. Based on the distribution of the reference genes,
we applied the Tukey’s interquartile rule for outliers56 to identify poor-quality RT-
qPCR data. In total, 16 samples (0.7%) were excluded from downstream analyses,
either for lack of sufficient RNA or because of spurious RT-qPCR results (due to
poor-quality mRNA). Therefore, 2319 patients in total (99.3%) were included in
the statistical analysis. EPN3 mRNA status was stratified into low and high, based
on the median of Cq normalized value, high EPN3 mRNA ≥28.18 or low EPN3
mRNA <28.18, respectively (Fig. 10c, d; Supplementary Tables 2 and 3).
EPN3 expression analysis in the IEO BC cohort by IHC on TMA. Three
micrometer sections from the TMA blocks were cut, mounted on glass slides, and
processed for IHC analysis using the in-house generated anti-hEPN3 mouse
monoclonal antibody (Ab, clone VI31, epitope: aa residues 464–483, Homosapiens)9
at a final concentration of 0.04 µgml−1. Following antigen retrieval in 1.0mM
EDTA pH 8.0, immunocomplexes were visualized by the EnVision™+HRP mouse
(DAB+ ) kit, DAKO (Catalog number: K4007), and acquired with the Aperio
ScanScope system (v12.2.2, Leica Biosystems). For scoring, a semi-quantitative
approach, with scores ranging from 0 (negative staining) to 3 (intense staining) in
0.5 unit increments, was used. EPN3 expression, measured in parallel in non-
neoplastic mammary gland areas of breast tissue samples (N= 32), was weak (IHC
score ≤1.0, median score= 0.5) in >90% of the cases (29/32); tumor samples with
IHC scores >1.0 were considered EPN3-high, and those with ≤1.0 were considered
EPN3-low. Of 2275 cases arrayed on TMA, reliable IHC data for EPN3 expression
was obtained in 1817 (79.9%) cases, mainly due to loss of tissue cores during staining
and/or lack of neoplastic tissue in the tissue core (Fig. 10c, d; Supplementary Tables 1
and 3).
IHC analysis of ERBB2 expression was repeated ad hoc, in this cohort, for this
study. Following antigen retrieval (1.0 mM EDTA pH 8.0, for 50 min at 95 °C),
TMA sections were incubated with a rabbit polyclonal anti-ERBB2 Ab (dilution
1:1000, 0.6 µg ml−1) from DAKO (Catalog number: A0485). Immunocomplexes
were visualized by the EnVision™+HRP Rabbit (DAB+ ) kit, DAKO (Catalog
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number: K4011), and acquired with the Aperio ScanScope system (v12.2.2, Leica
Biosystems). ERBB2 expression was evaluated according to the HercepTest™
(DAKO) scoring system.
FISH analysis of BC TMAs. The FISH analysis (Fig. 1b) was performed on a
cohort of BC patients available in the lab as TMAs57,58 and derived from a clinical
study (Trial registration ID: NCT00970983)12. The PathVysion HER-2 DNA Probe
Kit (Abbott Molecular Inc.) was employed to detect ERBB2 amplification on TMA
sections following the manufacturer’s instructions. To analyze EPN3 amplification,
the genomic clone CTD-2530L10, encompassing the hEPN3 gene, was selected
from the CalTech human BAC library D (CTD) (Thermo Fisher Scientific). DNA
probe was labeled with a fluorescent dye (Cy3-dUTP) (GE Healthcare Life Sci-
ences) by nick translation59. Briefly, 1 μg of DNA probe was incubated for 2 h at
16 °C in a mix (final volume, 30 μl) containing 50 mM Tris-HCl, 5 mM MgCl2 and
0.005% BSA, 4 μM dAGC (4 μM of dATP, dGTP, and dCTP each), 2.5 μM Cy3-
dUTP, 10 mM ß-mercaptoethanol, 0.3 μl DNA polymerase (20,000 units, Thermo
Fisher Scientific), 6 μl DNase (~0.017 units). The probe was ethanol-precipitated in
the presence of 3 μg salmon sperm DNA and 10 μg human Cot-1 DNA (Thermo
Fisher Scientific). After centrifugation, the dried pellet was resuspended in hybri-
dization mix (50% formamide, 10% dextran sulfate, and 2xSSC). The mixture was
then incubated with shaking for 10 min at RT. Once labeled, the DNA probe was
hybridized on dried slides of the BC TMAs, following the protocol of the Path-
Vysion HER-2 DNA Probe Kit (Abbott Molecular Inc.). Hybridized slides were
analyzed using fluorescent microscopy.
EPN3 was considered amplified when the EPN3/CEP17 ratio was >2.5; ERBB2
was considered amplified when the ERBB2/CEP17 ratio was ≥2.0 according to
Wolff et al.60. Reliable data on EPN3 and ERBB2 amplification were obtained on
219 samples (Fig. 1b). Cases in which results could not be obtained were due to loss
of tissue cores during staining and/or lack of neoplastic tissue in the tissue core.
On the same cohort, we performed the initial comparative analysis of EPN3
amplification vs. overexpression (Fig. 1c, d). The procedures for EPN3 IHC are
described above. In this case, we obtained reliable FISH and IHC results in 212
cases (Fig. 1d).
Constructs and plasmids. Full-length human EPN3 was isolated by RT-qPCR
from MDA-MB-361 cells and sequence-verified, followed by subcloning, as
appropriate, into the pBABE-Flag-puro retroviral vector (Figs. 2, 3, 4, 5, 7; Sup-
plementary S3, S4, S5, S7, S8, S9), pLVX-puro lentiviral vector (Supplementary
Figs. 2E and 6) or inducible pSLIK-neo lentiviral vector (gift from Iain Fraser,
Addgene plasmid # 25735; http://n2t.net/addgene:25735; RRID:Addgene_25735,
Fig. 7 and Supplementary Fig. 9C)61. Nucleotide sequences of the primers used for
the cloning:
EPN3 Reverse: GAAGATCTACGACCTCCGCACTCCGG
EPN3 Forward: GGAATTCTCAGAGGAAGGGGTTGGTGCC.
Full-length human EPN1 was isolated by RT-qPCR from MDA-MB-361 cells
and sequence verified, followed by subcloning, as appropriate, into the pBABE-
Flag-puro retroviral vector.
pBABE-puro-mTwist was a gift from Bob Weinberg (Addgene plasmid # 1783;
http://n2t.net/addgene:1783; RRID:Addgene_1783)15.
The pSicoR lentiviral vectors (gift from Tyler Jacks, Addgene plasmid # 11579;
http://n2t.net/addgene:11579; RRID:Addgene_11579)62 were used for constitutive
shRNA expression in DCIS.com cells (shEpn3#1, Fig. 9e, f; Supplementary
Fig. 10B, C) and in BT474 (shEpn3#1 and 2, Supplementary Fig. 2C, D). Vectors
were engineered to express shRNA specifically targeting Epn3 expression
(shEpn3#1, shEpn3#2) or luciferase (shLuc) and mismatch (shMis) as controls. The
following shRNA oligo sequences were used:
shEpn3#1 Forward:
TGCGAGAACCTCTACACCATTTCAAGAGAATGGTGTAGAGGTTCTCGCT
TTTTTC
shEpn3#1 Reverse:
TCGAGAAAAAAGCGAGAACCTCTACACCATTCTCTTGAAATGGTGTA
GAGGTTCTCGCA
shEpn3#2 Forward:
TGAGCTAGAAACTGAACGCCTTCAAGAGAGGCGTTCAGTTTCTAGC
TCTTTTTTC
shEpn3#2 Reverse:
TCGAGAAAAAAGAGCTAGAAACTGAACGCCTCTCTTGAAGGCGTTCA
GTTTCTAGCTCA
shOligoMis#1 Forward:
TGAGCGAACCGATACACTATTTCAAGAGAATAGTGTATCGGTTCGCT
CTTTTTTC
shOligoMis#1 Reverse:
TCGAGAAAAAAGAGCGAACCGATACACTATTCTCTTGAAATAGTGTA
TCGGTTCGCTCA
shOligoMis#2 Forward:
TGTGATAGGATCTGAACTCCTTCAAGAGAGGAGTTCAGATCCTATCA
CTTTTTTC
shOligoMis#2 Reverse:
TCGAGAAAAAAGTGATAGGATCTGAACTCCTCTCTTGAAGGAGTTCA
GATCCTATCACA.
Cell culture. All human breast cell lines were from the American Type Culture
Collection (ATCC), with the exception of MCF10DCIS.com, which were kindly
provided by Dr. John F Marshall (Barts Cancer Institute, London, UK)63. All
human cell lines were authenticated at each batch freezing by STR profiling (Ste-
mElite ID System, Promega), and tested for mycoplasma by PCR64 and bio-
chemical assay (MycoAlert, Lonza).
MCF10A and MCF12A cell lines were cultured in a 1:1 mixture of DMEM and
Ham’s F12 medium (Gibco, Life Technologies), supplemented with 5% horse
serum (Invitrogen), 2 mM L-glutamine, 20 ng ml−1 human EGF (Invitrogen), ng
ml−1 cholera toxin, 10 μg ml−1 insulin, and 500 ng ml−1 hydrocortisone (Sigma).
The HCC1569 cell line was cultured in the RPMI-1640 medium (Lonza),
supplemented with 10% FBS and 2mM L-glutamine. BT474, MCF7, SKBR3,
MDA-MB-453, and MDA-MB-361 cells were cultured in the DMEM medium
(Lonza), supplemented with 10% FBS and 2 mM L-glutamine (Euroclone). The
HMEC cell line was cultured in MEGM medium, supplemented with Bullet kit
(Lonza). MCF10DCIS.com were grown in the same culture medium of MCF10A
and MCF12A, in the absence of cholera toxin. All cells were cultured at 37 °C in a
humidified atmosphere containing 5% CO2.
MCF10A and MCF12A cells infected with stably overexpressing retroviral
constructs (pBABE-EPN3, -EPN1, -TWIST) or with pBABE empty vector, EV
(referred as Ctr) were selected with 2 μg ml−1 puromycin; HCC1569 cells infected
with stably overexpressing lentiviral constructs, pLVX-EPN3 and pLVX-EV
(referred as Ctr), were selected with 1.5 μg ml−1 puromycin.
Unless otherwise indicated, cells at low/medium confluency (30–60%) were
stimulated with different doses of TGFβ1 (0.75 or 5 ng ml−1) for the indicated time
points. Treatment with TGFβR kinase inhibitor LY2109761 (5 μM for 72 h), or
with the same concentration of the vehicle DMSO, was performed on MCF10A
cells at 40–50% confluency.
To generate doxycycline-inducible EPN3 expressing cells (Fig. 7), MCF10A-Ctr
cells were infected with pSLIK-neo lentiviral construct expressing EPN3 (referred
as EPN3dox) as or pSLIK-neo empty vector (Ctrdox). Selection was performed with
150 μg ml−1 neomycin. To induce EPN3 expression, cells were treated with 200 ng
ml−1 doxycycline for 6 and 24 h.
Reagents and antibodies. Human recombinant TGFβ1 was from Peprotech;
LY2109761 was purchased from Selleckbio. Duolink in situ Proximity Ligation
Assay (PLA) was from O-link Bioscience (Duolink In Situ Detection Reagents
Orange), and was performed according to the manufacturer’s directions.
Antibodies used in the study are described in Supplementary Table 4 (primary
antibodies) and Supplementary Table 5 (secondary antibodies).
RNA interference (RNAi). RNAi was performed with Lipofectamine RNAimax
reagent from Invitrogen, according to the manufacturer’s instructions.
For transient KD of EPN3 (Fig. 5f, g), cells were subjected to single reverse
transfection with 10 nM RNAi oligos and analyzed 3 days after transfection. The
following RNAi oligo (Dharmacon) was used: GUACAAGGCUCUAACAUUG. As
a control, the following non-targeting siRNA oligo (Dharmacon) was used (D-
001810-01-05): UGGUUUACAUGUCGACUAA.
For transient TCF4 KD (Figs. 4f, 6c, d; Supplementary Fig. 8D), cells were
subjected to two cycles of reverse transfection at day 0 and day 4 with 20 nM of
iBONI siRNA pool (Riboxx), with the following sequences:
AUAAUACAGAACCAACUCCCCC
UUCUUCCAAACUUUCCCGGCCCCC
UUAAAGUCUGCUGCCUACCCCC.
For transient KD of TGFβ receptors (Figs. 6c, d, 8f, g; Supplementary Fig. 8B,
D), cells were subjected to double transfection (reverse) with 8 nM smart pool of
RNAi oligos and analyzed 4–7 days after transfection. As negative control siRNA,
we used “All Stars” from Qiagen or mock-silenced cells.
The following RNAi oligos from Dharmacon were used:
- TGFBR1 smart pool:
GAGAAGAACGUUCGUGGUU
UGCGAGAACUAUUGUGUUA
GACCACAGACAAAGUUAUA
CGAGAUAGGCCGUUUGUAU
- TGFBR2 smart pool:
CAACAACGGUGCAGUCAAG
GACGAGAACAUAACACUAG
GAAAUGACAUCUCGCUGUA
CCAAUAUCCUCGUGAAGAA
Quantitative real-time PCR analysis. The total RNA was extracted from cells
(Figs. 2d, 5d, 5g, 6a, 6d, 7c; Supplementary Figs. 2A, 3B, 5F, 6C, E, 7B, 8A, B, D, 9A,
C) using the RNeasy kit from Qiagen, according to the manufacturer’s protocol.
Single-stranded cDNA synthesis was performed using the SuperScriptII reverse
transcriptase (Invitrogen) following the manufacturer’s instructions. Briefly, 1 μg of
the total RNA was mixed with 250 nM of random primers in RNase-free water and
then incubated at 70 °C for 5 min. Following incubation, 10× reaction buffer,
dNTPs mix (0.5 mM final concentration), and 1 μl of reverse transcriptase were
added to the mix (20 μl final volume), and the reaction was incubated at 42 °C for
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1 h. Finally, the reaction was inactivated by heating at 70 °C for 15 min. Taqman
gene expression assays were as follows: Hs00978957_m1 (EPN3), Hs00170423_m1
(CDH1), Hs00169953_m1 (CDH2), Hs00185584_m1 (VIM), Hs00998133_m1
(TGFB1), Hs00234244_m1 (TGFB2), Hs00610320_m1 (TGFBR1),
Hs00234253_m1 (TGFBR2), Hs00232783_m1 (ZEB1), Hs99999903_m1 (ACTB),
Hs99999901_s1 (18 S), and Hs99999905_m1 (GAPDH).
Unless otherwise indicated in the figure legend, the data were normalized on the
average expression of the housekeeping genes 18S-ACTB-GAPDH, and reported as
relative fold change compared with Ctr/not treated cells, mean ± S.D.
The list of primers used in the study can be found in Supplementary Table 6.
EPN3 transcripts and copy number analysis in breast cells. The total RNA
(Supplementary Fig. 2A) and genomic DNA (Supplementary Fig. 2B) were
simultaneously extracted from fresh/frozen (FF) breast cell lines using the AllPrep
DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany) automated on
QIAcube, following the manufacturer’s instructions (Qiagen, Hilden, Germany).
For EPN3 and ERBB2 mRNA analysis, 500 ng of the total RNA (RNA
concentration measured using the NanoDrop® ND-1000 Spectrophotometer) were
reverse transcribed with random primers using the SuperScript® VILO™ cDNA
Synthesis Kit (Thermo Fisher Scientific), and 5 ng of cDNA/reaction was analyzed
by PCR. Quantitative PCR was performed with hydrolysis probes (Thermo Fisher
Scientific) using the SsoAdvanced Universal Probes Supermix (Bio-Rad
Laboratories) in 10 μl final volume in 384-well plates. PCR reaction was run in
LightCycler (LC) 480 real-time PCR instruments (Roche) using the following
thermal cycling conditions: 1 cycle at 95 °C for 30 s, 45 cycles at 95 °C for 5 s, and
60 °C for 30 s. TaqMan gene expression assays were as follows: Hs00978957_m1
(human EPN3, RefSeq NM_017957.2, exon boundary 5–6, assay location 1328,
amplicon length 62 bp) and Hs03929097_g1 (human GAPDH, RefSeq
NM_001256799, exon boundary 8–8, assay location 1250, amplicon length 58 bp).
Custom TaqMan gene expression assay to detect ERBB2 mRNA was designed
using the Primer Express software (v3.0, Thermo Fisher Scientific):
Forward primer: GGATGTGCGGCTCGTACAC
Reverse primer: TAATTTTGACATGGTTGGGACTCTT
Probe-FAM: ACTTGGCCGCTCGG
Each target was assayed in triplicate, and average Cq values were calculated (the
average was calculated from triplicate values when the standard deviation was <0.4,
or from the best duplicate values when the standard deviation was ≥0.4). Data
(average Cq) were normalized to the average Cq value of the endogenous reference
gene (GAPDH), and to MCF10A as calibrator sample using the comparative Cq
(2−ΔΔCq) method (Supplementary Fig. 2A). RT-qPCR experiments were performed
three times.
For EPN3 and ERBB2 gene copy number analysis, we used real-time
quantitative PCR. Genomic DNA (1 μg) was digested with HaeIII prior to PCR
analysis. Digested DNA (10 ng) was analyzed using the SSAdvanced Universal
Probes Supermix (Bio-Rad Laboratories) in 10 μl final volume in 384-well plates.
PCR was run in LightCycler (LC) 480 real-time PCR instruments (Roche) using the
following thermal cycling conditions: 1 cycle at 95 °C for 30 s, and 45 cycles at
95 °C for 5 s and 60 °C for 30 s. TaqMan copy number assays were as follows:
Hs03036374_cn (human EPN3, Chr.17:48613920, amplicon length 77 bp) and
Hs02803918_cn (human ERBB2, NG_007503.1, Chr.17:37881203, amplicon length
70 bp). Custom TaqMan copy number assay to control for chromosome 17
(CEP17) was designed using the Primer Express software (v3.0, Thermo Fisher
Scientific):
Forward primer: TTGCAGCACGTGGCACAT
Reverse primer: ACGGCAGCAAGAGAGGAAAG
Probe-FAM: CACTGCCTGAGCACC
Three independent PCR experiments were performed for each cell line, and
each target was assayed in triplicate. Average Cq values were calculated (the
average was calculated from triplicate values when the standard deviation was <0.4,
or from the best duplicate values when the standard deviation was ≥0.4). Each
replicate of either EPN3 or ERBB2 was normalized to centromeric probe CEP17 to
obtain a ΔCq, and then an average ΔCq for each sample (from the three replicates)
was calculated. All samples were then normalized to MCF10A used as calibrator
sample (2n genome for chromosome 17) to determine ΔΔCq. Relative quantity
(RQ) is 2−ΔΔCq, and copy number is 2 × RQ (Supplementary Fig. 2B).
The list of primers used in the study can be found in Supplementary Table 6.
Cell lysis and immunoblot (IB). Cells were lysed in RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS), supplemented with a protease inhibitor cocktail (CALBIOCHEM) and
phosphatase inhibitors (20 mM Na-pyrophosphate pH 7.5, 50 mM NaF, 10 mM
Na3VO4 pH 7.5). Lysis was performed directly in the cell culture plates using a cell-
scraper, and lysates were clarified by centrifugation at 16,000 g for 10 min at 4 °C.
Protein concentration was measured by the Bradford assay (Biorad) following the
manufacturer’s instructions. Proteins were transferred to nitrocellulose filters.
Filters were blocked for 1 h (or overnight) in 5% milk in TBS (50 mM Tris-HCl, pH
7.4, 150 mM NaCl) supplemented with 0.1% Tween (TBS-T). After blocking, filters
were incubated with the primary Ab, diluted in TBS-T 5% milk, for 1 h at RT or
overnight, followed by three washes of 5 min each in TBS-T. Filters were then
incubated with the appropriate horseradish peroxidase-conjugated secondary Ab
(anti-mouse IgG HRP-linked 7076 or anti-rabbit IgG HRP-linked 7074, Cell Sig-
naling) diluted 1:2000 in TBS-T for 30 min. After three washes in TBS-T (5 min
each), the bound secondary Ab was revealed using the ECL method (Amersham)
with Image Lab software (v3.0, Bio-Rad Laboratories).
For several IB experiments, samples were loaded on different gels (since many
proteins have similar molecular weight), which were subsequently cut in the region
of interest to allow detection with multiple Ab. Reblotting was also performed in
some cases (see Source Data for details).
Quantitations of IBs in Fig. 2c and Supplementary Fig. 8C were obtained
through the Gel Analysis Plug In of ImageJ software (v1.52, NIH). Each sample was
normalized to its corresponding loading control and expressed as relative fold
change compared with its control sample, as specified in legends to Fig. 2c and
Supplementary Fig. 8C.
Co-immunoprecipitation (Co-IP). For co-IP experiments (Fig. 4d), MCF10A-Ctr
and -EPN3 cells were plated on 150-mm plates. After 48 h, cells were washed twice in
PBS and EGF starved overnight. Cells (at a confluence between 80 and 95%) were
then washed twice in PBS and subjected to cross-linking (formaldehyde 1% in
ddH2O) for 10min at RT with shaking. Buffer was removed and a glycine buffer
(glycine 0.125M in ddH2O) was added to cells for 5 min at RT with shaking. Cells
were washed twice with cold PBS and lysed in RIPA buffer by scraping directly on
plates (300 µl RIPA buffer/150-mm plate, see “Cell lysis and immunoblot” paragraph
for detailed information). Cells were left 30 min on ice, followed by sonication
(20 cycles at 4 °C: 30 s of sonication and 30 s of pause) and centrifugation at 16,000 g
at 4 °C for 40min (protocol adapted from ref. 65). A pre-clearing step was performed
by incubating the supernatants with Protein G for 1 h at 4 °C with rotation. Protein
concentration was quantified in lysates with the Bradford Assay (Biorad) before
performing the co-IP experiments. Co-IP was performed with the anti-EPN3 Rabbit
polyclonal Ab, at a concentration of 5 ngmg−1 of fresh lysate, in a volume of 400 µl.
The lysate-Ab mixture was incubated for 2 h at 4 °C with rotation. Protein G was
added and incubated for an additional 1 h. Samples were washed four times in RIPA
buffer, and elution was performed in Laemmli buffer 2×.
ECAD staining at the cell-to-cell junction. MCF10A-Ctr, -EPN1, -EPN3, and
TWIST cells were grown at confluency on coverslips for 48 h. Cell were fixed with
4% PFA and subjected to IF with anti-ECAD Ab (BD Bioscience) and DAPI
staining (Fig. 4a; Supplementary Fig. 4A). Briefly, cells were permeabilized in PBS
0.1% Triton X-100 for 10 min at RT. To prevent nonspecific binding of the Ab,
cells were incubated with PBS in the presence of 5% BSA for 30 min and then with
primary Ab diluted in PBS (+ 0.2% BSA) for 1 h at RT. Coverslips were washed
three times with PBS and incubated for 30 min at RT with secondary Ab Alexa-
488-conjugated (green, donkey anti-mouse IgG, A-21202, Thermo Fischer, dilution
1:400). After three washes in PBS, coverslips were mounted in a 90% glycerol
solution containing diazabicyclo-(2.2.2)octane antifade (Sigma). Images were
obtained using a Leica TCS SP2 or TCS SP2 AOBS confocal microscope equipped
with a 63× oil objective and processed using ImageJ software (v1.52, NIH).
ECAD and EPN3 co-localization. Co-localization between ECAD and EPN3
(Fig. 5c) was performed using an anti-ECAD Ab (HECD-1) from Abcam, recognizing
the extracellular domain of ECAD66. Briefly, MCF10A-Ctr or -EPN3 cells were plated
on coverslips at ~30% confluence. Cells were starved overnight in culture medium
containing 5% horse serum in absence of EGF. After starvation, coverslips were
washed with PBS and incubated with the anti-ECAD Ab (2 μg ml−1) for 1 h at 4 °C.
The time zero sample was immediately fixed with 4% PFA. The other samples were
incubated at 37 °C for 90min with culture medium containing 5% horse serum and
TGFβ (5 ngml−1). After incubation cells were fixed with 4% PFA, followed by IF (as
described in the Paragraph: “ECAD staining at the cell-to-cell junction”). Cells were
stained with anti-EPN3 rabbit polyclonal Ab (50 ngml−1). EPN3 and ECAD signals
were then revealed with secondary Ab Cy3-conjugated (red, donkey anti-rabbit IgG
715-165-152, Jackson ImmunoResearch, dilution 1:400) or Alexa-488-conjugated
(green, donkey anti-mouse IgG 715-165-150, Jackson ImmunoResearch, dilution
1:400), respectively. Images were obtained using a Leica TCS SP2 or TCS SP2 AOBS
confocal microscope equipped with a 63× oil objective and processed using ImageJ
software (v1.52, NIH).
IF analysis of active β-catenin. MCF10A-Ctr and -EPN3 cells (150,000 cells) were
plated on coverslips into six-well plates. After 48 h, cells were fixed/permeabilized
in methanol for 10 min at −20 °C, washed with PBS, and blocked with 2% BSA to
prevent nonspecific binding. Cells were stained with anti-active β-catenin (Milli-
pore 8E7) diluted in PBS 0.2% BSA for 1 h. After three washes with PBS, cells were
incubated for 1 h with secondary Ab (donkey anti-mouse Alexa-488-conjugated,
A-21202, or donkey anti-mouse Alexa-647-conjugated, A-31571, Thermo Fisher,
dilution 1:400). Cells were then stained with DAPI (Sigma) for 5 min. Finally, after
three washes with PBS, coverslips were mounted on a 90% glycerol solution
(Sigma) and examined under a confocal microscope (AOBS SP2, SP5 or SP8,
Leica). Images were processed with ImageJ software (v1.52, NIH). For each image
(.tiff), a DAPI mask was used to identify nuclei and to measure the mean fluor-
escence intensity of active β-catenin in the nucleus for each cell. Finally, active
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β-catenin staining in nuclei was reported as relative fold change compared with Ctr
cells (Figs. 4e and 7f, g).
Analysis of surface ECAD signal intensity by FACS. MCF10A-Ctr, -Mock, or
-EPN3-KD cells (8 × 105), or MCF10A-EPN3 cells (1.2 × 105) were plated on
35-mm dishes. After 36 h, cells (at 60–80% confluency), were washed twice with
PBS and incubated for 3 h with medium without EGF. Cells were stained with anti-
ECAD Ab (Abcam, 2 µg ml−1) for 1 h at 4 °C, followed by incubation with sec-
ondary Ab (donkey anti-mouse IgG Alexa-488-conjugated, 5 µg ml−1, A-21202,
Thermo Fisher) for 30 min at 4 °C. Cells were then washed twice with PBS and
detached from the plates with trypsin 0.25% (15–20 min at 37 °C). Cells were
recovered in medium in a 15 ml Falcon, washed once with PBS, resuspended in
500 µl PBS, and fixed by adding 500 µl of formaldehyde 2% for 15 min on ice.
Subsequently, cells were centrifuged at 335 g for 5 min and resuspended in PBS
with EDTA 2mM before analysis with the FACS Celesta (BD). Samples stained
only with secondary Ab were used as a negative control. Samples stained for ECAD
and fixed or not with formaldehyde 2% were compared to evaluate the effect of
fixation: no significant difference was observed both in fluorescence intensity and
in number of cells positively stained. Analysis was performed using the FlowJo
software (v10.4.2, LLC). Briefly, cell doublets and clumps were excluded through
the side scatter area (SSC) over the height peak parameter. Cells with correct
morphology were then selected through the forward scatter area (FSC) over SSC
area parameters. Finally, ECAD mean fluorescence intensity of the population was
used to compare the different samples.
ECAD internalization assay by FACS. FACS analyses were used to follow ECAD
internalization (Figs. 4c, 5b, 5f, 7e). Cells were subjected to the same protocol
described in “Analysis of PM-ECAD signal intensity by FACS”. In this case, after
the incubation with anti-ECAD and secondary Ab, cells were washed twice with
PBS and re-incubated at 37 °C with complete medium ± TGFβ 5 ng ml−1. At the
indicated time points, cells were washed once with cold PBS and treated with acid
wash (AW) solution (glycine 0.1 M in ddH2O, pH= 2.2) on ice for three times, 45
sec/each. Cells were then washed twice with PBS, and detached from the plates with
trypsin 0.25% (15–20 min at 37 °C). Subsequently, cells were fixed and processed as
described in “Analysis of PM-ECAD signal intensity by FACS”. To evaluate the
amount of internalized ECAD, the mean fluorescent intensity of internalized
ECAD for each time point was divided by the total ECAD fluorescent intensity.
The time 0 min was set as background, and its value subtracted from the other time
points.
ECAD internalization assays by IF. IF was used to follow ECAD internalization
(Figs. 5a, 7d). Cells were subjected to EGF-starvation for 3 h, then stained with
anti-ECAD Ab (Abcam, 2 µg ml−1) for 1 h at 4 °C. Then, cells were washed twice
with PBS and re-incubated at 37 °C with complete medium ± TGFβ 5 ng ml−1. At
the indicated time points, cells were washed once with cold PBS and treated with
acid wash (AW) solution (glycine 0.1 M in ddH2O, pH= 2.2) on ice for three
times, 45 s/each. Cells were then washed twice with PBS, fixed for 10 min with PFA
4% at RT, incubation with secondary Ab (donkey anti-mouse IgG Alexa-488-
conjugated, 5 µg ml−1, A-21202, Thermo Fisher) for 30 min, by DAPI staining and
confocal microscopy analysis (AOBS SP2, SP5 or SP8, Leica). Images were pro-
cessed with ImageJ software (v1.52, NIH). For each image (.tiff), different fields of
view for each image were isolated and quantified by Integrated Density (IntDen) to
evaluate signal intensity for the different samples. The number of cells for each field
of view was counted, and the IntDen was divided by the number of cells per field of
view. Finally, ECAD intensity was reported as relative fold change compared with
the indicated sample (Figs. 5a, 7d).
125I-EGF, 125I-TGFβ internalization and recycling assays. MCF10A cells were
plated in 24-well plates (50,000/well) in triplicate for each time point, plus one well
to measure nonspecific binding. The day after, cells were starved for at least 4 h in
MCF10A standard medium without EGF (supplemented with 20mM Hepes and
0.1% BSA) and then incubated at 37 °C in the presence of 1.5 ngml−1 125I-EGF
(Supplementary Fig. 5C, D) or 0.75 ngml−1 of 125I-TGFβ (Supplementary Fig. 5A,
B). At different time points (2, 4, 6 min), cells were placed on ice, washed twice in
cold PBS, and then incubated for 5 min at 4 °C in 300 μl of acid wash solution (0.2M
acetic acid, 0.5M NaCl, pH 2.5). The radioactivity recovered in the acid wash
represents the amount of ligand bound to the receptor on the cell surface. Cells were
then lysed with 300 μl of 1 N NaOH, which represents the amount of internalized
ligand. Nonspecific binding was measured at each time point in the presence of an
excess of non-radioactive EGF (300 times) or TGFβ (500 times). After being cor-
rected for nonspecific binding, the data were plotted as the ratio between internalized
and surface-bound radioactivity over time. Recycling of 125I-TGFβ was assessed by
starving MCF10A cells for at least 2 h in standard medium without EGF (supple-
mented with 0.1% BSA, 20mM Hepes), and incubating cells with 0.75 ngml−1 of
125I-TGFβ at 37 °C. Cells were then chased at 37 °C in a medium containing 375 ng
ml−1 cold TGFβ for the indicated times to allow recycling and then processed
following the protocol described for 125I-EGF recycling assay67.
ELISA assay. ELISA assay to measure TGFβ1 concentrations in MCF10A cell
culture medium (Fig. 6b; Supplementary Fig. 8A) was performed according to the
manufacturer’s instructions (Human TGFβ1 Quantikine ELISA Kit, R&D). Briefly,
cells were plated in 150-mm dishes with 20 ml of complete medium, at least two
dishes per each condition. When cells reached confluency, after 2 days from
plating, they were serum starved for 24 h in 10 ml of complete medium without
serum. The following day, cell culture media were concentrated, using Amicon
Ultra 15 10 KDa cutoff tubes (Merck), to ∼750 μl. Supernatants were then activated
to detect latent TGFβ1 in the medium with 1 N HCl for 10 min, neutralized with
1.2 N NaOH/0.5 M HEPES, and immediately spotted onto microplates coated with
monoclonal Ab anti-TGFβ1 for 2 h at RT. Wells were washed three times with the
manufacturer’s wash buffer and then treated with anti-TGFβ1 conjugated with
horseradish peroxidase for 2 h at RT. After three more washes, substrate solution
(hydrogen peroxide and stabilized chromogen tetramethylbenzidine) was added for
30 min at RT. Finally, stop solution (hydrochloric acid) was added, and plate
absorbance was immediately read at Glomax (Promega) at the specific wavelength
of 450 nm and at the nonspecific wavelength of 750 nm. Cell culture supernatants
of each dish were assayed in triplicate, together with duplicates of known TGFβ
concentrations (standards), which were used to create a standard curve and to
calculate the equation of the curve and hence derive the concentration of TGFβ in
cell culture supernatants. The concentration of TGFβ was divided by the number of
cells on the day of the experiment and normalized for 10 million cells. Data were
reported as pg ml−1 10−6 cells.
CD44–CD24 flow-cytometry analysis. Cells were stained with the anti-CD44 and
anti-CD24 Ab diluted 1:5 in 1% BSA (100 μl/500,000 cells) and then fixed in 1%
formaldehyde and analyzed by BD FACSCantoII (Fig. 8a, f; Supplementary
Fig. 10A). BD FACSAria was used to sort live cells into CD44high/CD24low and
CD44low/CD24high populations (Fig. 8d, e). Nonstained cells were used as a
negative control to establish the background fluorescence. Gating on FSC com-
pared with SSC was initially applied to isolate viable single-cell populations; then
single-stained cells were used to set the gates for each dye used; finally, additional
gating was used to select for CD44high/CD24low population in Fig. 8a, f. The
CD44high/CD24low population is also represented as histograms for CD24 and
CD44 in Supplementary Fig. 10A. Flow-cytometric analysis was performed using
BD FACSDiva software (v8.0.1.1, BD).
For IB analysis on the sorted populations (Fig. 8e), CD44high/CD24low and
CD44low/CD24high populations were re-plated after sorting, and lysed after 48 h.
FACS analysis with CD44/CD24 markers was performed immediately after sorting
to control for the purity of the two populations.
Mammosphere assay. Unsorted or sorted single-cell suspensions (10,000 cells ml−1)
were plated on ultralow attachment plates coated with Poly-HEMA, embedded in 1%
methylcellulose in complete stem cell medium35: MEBM (Lonza) supplemented with
1% glutamine, 1% penicillin–streptomycin antibiotics, insulin 5 μgml−1, hydro-
cortisone 0.5 μgml−1, heparin 1 U ml−1, growth factors and supplement (freshly
added): EGF 20 ngml−1 (Peprotec), FGF 20 ngml−1 (Peprotec) and B27 supplement
(Gibco) (Fig. 8c, d). After 10 days, images of mammospheres were acquired through
confocal microscopy (Leica TCS SP5 AOBS microscope system with Las-X software,
v3.5 Leica Biosystems, equipped with Leica HyD and PMT detectors); spheres with
diameter >50 μm were counted, and data were reported as sphere-forming efficiency
(SFE: number of spheres/number of plated cells × 100).
Matrigel MCF10A morphogenetic assay. MCF10A cells were suspended in their
culture medium containing 5 ng ml−1 EGF (instead of 20 ng ml−1 of standard
medium) and 2% of growth factor reduced Matrigel (Corning). Cells (1000 cells/
well) were plated on eight-well or four-well glass slides (chamber slide system, Lab-
Tek II) on a thin layer of Matrigel (~60 μl, previously allowed to solidify on the
bottom of the plate). Cells were incubated at 37 °C, 5% CO2 for 14/21 days.
Medium was changed every 3 days (Fig. 2f, g; Supplementary Fig. 3C, D). Images
were acquired using a phase-contrast microscope at an initial time point of the
morphogenetic program, day 5 (Supplementary Fig. 3C), and at completion of the
morphogenetic program (days 14–21, depending on the experiment as described
below, Fig. 2f, g; Supplementary Fig. 3D), and processed with ImageJ software
(v1.52, NIH). For images acquired at day 5, acini were counted and measured for
their diameter to discriminate organoids larger or smaller than 50 μm (Supple-
mentary Fig. S3D). As the completion of the morphogenetic program was variable
among experiments, samples were either stopped at 14 days or at 21 days in
individual experiments. Images were acquired, and acini larger than 50 μm were
counted. Circularity was measured by ImageJ software (v1.52, NIH) to quantify
regular and irregular organoids (circularity larger or smaller than 0.8, respectively)
in each experiment. Results are expressed as mean ± S.D. of independent experi-
ments (see Fig. 2f, bottom).
For IF staining of the acini with Laminin V and Giantin (Fig. 2g), slides were
fixed directly in eight-well chamber slides with 4% paraformaldehyde for 20 min at
RT and permeabilized with 0.5% Triton X-100 in PBS for 10 min at 4 °C. For IF
staining of the acini with ECAD and active β-catenin (Fig. 7g), slides were fixed
directly in the four-well chamber slides with methanol for 20 min at −20 °C. Slides
were rinsed three times with PBS/Glycine (100 mM), 10 min/wash at RT. Blocking
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16836-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3020 | https://doi.org/10.1038/s41467-020-16836-y |www.nature.com/naturecommunications 17
was in 10% goat or donkey serum in PBS (with 0.1% BSA, 0.2% Triton X-100,
0.05% Tween-20). Primary Ab anti-epiligrin (Laminin 5, Millipore), anti-giantin
(Babco), anti-ECAD (BD Bioscience), and anti-active β-catenin (Millipore) were
diluted in blocking solution and incubated overnight at 4 °C. Secondary Abs
(donkey anti-mouse or anti-rabbit, Alexa-488- or Alexa-647-conjugated, Thermo
Fisher; donkey anti-mouse or anti-rabbit Cy3, Jackson ImmunoResearch) were
diluted 1:200 in blocking solution and incubated for 40 min at RT. Nuclei were
counterstained with DAPI. Images were acquired on glass-wells with a Leica TCS
SP2 or TCS SP2 AOBS confocal microscope with Las-X software (v3.5, Leica
Biosystems) and processed using ImageJ software (v1.52, NIH). Active β-catenin
staining in nuclei was quantified as described in Paragraph “IF analysis of active β-
catenin”, and is reported as relative fold change compared with EV (Fig. 7g).
Soft-agar assay. The bottom agar layer was prepared from a 5% agarose stock
solution (GIBCO) that was dissolved in the microwave and mixed with culture
medium at a final concentration of 1%. The solution was dispensed (4 ml/well) in
six-well plates and allowed to harden at 4 °C for 30 min. Cells were trypsinized and
counted, and a cellular suspension of 25,000 cells ml−1 was prepared. Then, 1 ml of
the cellular suspension was added to 3 ml of medium containing 0.4% of agar, and
the total 4 ml of cells and agar were plated in six-well plates and incubated for
3 weeks (Supplementary Fig. 2C). Colonies were counted utilizing a phase-contrast
microscope.
Invasion assay. Growth Factor Reduced Matrigel invasion chambers placed on 24-
well plates from BD were used (Figs. 2e and 5e). Cells were trypsinized, resus-
pended in culture medium, and counted. In total, 40,000 cells were resuspended in
500 μl of culture medium and added to the top chamber of the transwell, and
incubated at 37 °C for 24 h. In the case of TGFβ stimulation, culture medium
supplemented with 0.75 ng ml−1 TGFβ was added to the lower chamber. After 24 h
of incubation, transwells were washed with PBS and fixed with PFA 4% for 20 min.
Transwell filters were stained with crystal violet for 20 min, and then extensive
washes with MilliQ H2O were performed. Stained membranes were used to take
photographs of the cells and for quantification.
In vivo xenografts. Cells were trypsinized and resuspended in medium, followed
by centrifugation at 300×g for 5 min and resuspension in 10 ml of PBS. Following
cell count, the desired number of cells was centrifuged again in at 300×g for 5 min
and resuspended in 40 μl of a 1:1 Matrigel-PBS solution, and immediately injected
into the inguinal mammary fat pad of NOD/SCID IL2R gamma-chain null (NSG)
female mice (6–8-weeks old). BT474 cells, either silenced for EPN3 (KD, sh#1) or
mock-silenced (shLUC), were injected into opposite inguinal mammary fat pads of
a female NSG mice (300,000 cells/injection, N= 8, number of injected mice).
Tumors were grown for 13 weeks before being explanted (Supplementary Fig. 2D).
EPN3-overexpressing HCC1569 (EPN3) or control vector-infected (Ctr) cells were
injected into opposite inguinal mammary fat pads of a female NSG mice (1,000,000
cells/injection, N= 8, number of injected mice). Tumors were grown for 43 days
before being explanted (Supplementary Fig. 2E).
MCF10DCIS.com cells, either silenced for EPN3 (DCIS-shEPN3) or mock-
silenced (DCIS-Ctr), were injected into inguinal mammary fat pad of NSG female
mice (100,000 cells/injection; number of injected mice, N= 19 for DCIS-Ctr and
N= 21 for DCIS-shEPN3). Tumors were grown for 2, 3, 4, or 5 weeks, as indicated
in legends (Fig. 9b–f; Supplementary Fig. 10B, C).
In each case, all injections in NSG mice were performed by resuspending cells in
20 μl of 3:1 PBS-Matrigel mix and injecting them into the inguinal mammary fat
pad of NSG female mice, after intraperitoneal anaesthetization with 150 mg kg−1
tribromoethanol (Avertin). Mice were monitored by hand-palpation for tumor
development. Tumor growth was measured with a Vernier caliper by applying the
standard formula: tumor volume= (length × width2)/2. Mice were sacrificed when
tumors reached a dimension of 0.5–1 cm3. Tumors were explanted and processed
for cell extraction or inclusion in FFPE. P values were calculated using the two-
tailed Student’s t test.
IHC analysis on MCF10DCIS.com xenografts. Three-μm sections were prepared
from formalin-fixed paraffin-embedded MCF10DCIS.com xenograft and dried at
37 °C overnight. The sections were processed with Bond-RX fully Automated
stainer system (Leica Biosystems) according to the following protocol. First, tissues
were deparaffinized and pre-treated with the Epitope Retrieval Solution 1 (pH 6) at
100 °C for 20 min for ECAD staining, 40 min for hEPN3, or Epitope Retrieval
Solution 2 (pH 9) at 100 °C for 20 min for NCAD. After washing steps, peroxidase
blocking was performed for 10 min using the Bond Polymer Refine Detection Kit
(#DC9800, Leica Biosystems). Tissues were incubated for 30 min with mouse
monoclonal Ab anti-ECAD (BD, #610182, 1:1500), mouse monoclonal anti-hEPN3
(clone VI31 in-house, 1:30000) or mouse monoclonal anti-NCAD (Dako, #M3613,
1:50) diluted in Bond Primary Ab Diluent (#AR9352). Subsequently, tissues were
incubated with post primary and polymer for a total of 16 min, developed with
DAB-chromogen for 10 min and counterstained with hematoxilin for 5 min.
For α-SMA and p63 Ab, we performed a double sequential automated staining;
tissues were pre-treated with the Epitope Retrieval Solution 1 (pH 6) at 100 °C for
20 min, incubated with rabbit monoclonal anti p63 (Abcam, ab124762, 1:8000),
and subsequently with mouse monoclonal anti α-SMA Ab (Dako, # 80851, 1:200).
Tissues were then incubated with post primary and polymers, respectively Polymer
Refine Red Detection Kit (#DS9390) for p63 or Bond Polymer Refine Detection Kit
(#DC9800) for α-SMA. Finally the sections were counterstained with hematoxilin
for 5 min and acquired with the Aperio ScanScope system (v12.2.2, Leica
Biosystems).
Generation of inducible EPN3-KI mice. An inducible EPN3 knock-in mouse
model (EPN3-KI) was generated by the OzGene company (Bentley, Australia). The
KI strategy is based on the targeted insertion of the human EPN3 cDNA
(NM_017957.3) into the ROSA26 locus. Expression of the transgene is under the
human Ubiquitin C promoter (UbiC), which is known to produce high-level
expression in transgenic mice68. A loxP-flanked STOP cassette, which contains
signals designed to prevent transcription of the gene of interest, is placed between
the promoter and the coding sequence. The STOP cassette can be removed using
Cre recombinase leading to the Inducible expression of the transgene. The EPN3-
KI mice were back-crossed into FVB background to obtain FVB EPN3-KI mice for
experiments.
Mouse mammary bilayered organoid culture. To obtain organoids with double
acini layer, inguinal and thoracic mammary glands from EPN3-KI mice of
6–12 weeks of age were used. Bilayered organoids were prepared essentially as
described in ref. 69, with modifications. Briefly, mammary glands were minced with
scissors and partially digested on a rotating wheel (1×g) for 1 h at 37 °C (5% CO2),
in the following digestion medium: 1:1 mixture of DMEM and Ham’s F12 medium
(DMEM/F12, Gibco, Life Technologies), 1% penicillin–streptomycin antibiotics,
trypsin 2.5% and collagenase type-1a 1 mgml−1 (Sigma-Aldrich, Merck Millipore).
Then, mammary glands were centrifuged for 5 min at 350 ×g and a three-layers
suspension was obtained. The liquid interface was discarded, while the fat layer (on
the top) was transferred into a new tube, diluted with PBS and centrifuged for 10
min at 350×g. The pellet was resuspended in DMEM/F12 and added to the pellet of
the first centrifugation. Samples were centrifuged again, and the pellet was treated
with ACK lysis buffer (Gibco, Life Technologies) for 1 min to lyse blood cells,
followed by dilution with PBS and centrifugation for 5 min at 350×g. The pellet was
resuspendend in MEGM medium supplemented with Bullet kit (Lonza), and
incubated for 30 min into a cell culture dish to allow the attachment of fibroblasts.
Then, supernatant containing non-attached cells was passed through a 40-μm
diameter filter, and the organoids trapped in the filter were resuspendend in
MEGM medium and transferred into a nonadherent dish.
Organoids were treated or not with 100 μg ml−1of CRE in Optimem medium
(Gibco, Life Technologies) for 2 h at 37 °C (5% CO2). Then, they were
centrifuged (350×g for 5 min), resuspendend in MEGM medium and left
overnight into a nonadherent dish. The CRE treatment was repeated the
following day. After 5 days of recovery in nonadherent conditions in MEGM
medium, organoids were then collected from the supernatant, counted, and
resuspended in MEGM medium containing 2% of growth factor reduced
Matrigel (Corning): 500–1000 organoids/well were plated in eight-well glass
slides (chamber slide system, Lab-Tek II) on a thin layer of Matrigel (~60 μl,
previously allowed to solidify on the bottom of the plate). Organoids were
incubated at 37 °C, in 5% CO2 for 10–14 days. Medium was changed every
3 days (Fig. 3a, b; Supplementary Fig. 3E). Images were acquired using a phase-
contrast microscope. Quantification was obtained by counting the number of
invasive vs. non invasive organoids per field of view.
For IF staining of the organoids (Fig. 3a, b; Supplementary Fig. 3E), slides
were fixed directly in the eight-well chamber slides with 4% paraformaldehyde
for 20 min at RT. Permeabilization was performed with 0.2% Triton X-100 in
PBS for 30 min at 4 °C and 30 min at RT. Slides were rinsed three times with PBS
(10 min/wash at RT). Blocking was in 1% bovine albumin serum in PBS (with
0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20). Primary Abs, anti-keratin-5,
anti-keratin-8, anti-keratin-14, anti-ECAD, anti-NCAD, and anti-EPN3, were
diluted in blocking solution and incubated overnight at 4 °C. Secondary Abs
(donkey anti-mouse or anti-rabbit, Alexa-488- or Alexa-647-conjugated,
Thermo Fisher; donkey anti-mouse or anti-rabbit Cy3, Jackson
ImmunoResearch) were diluted 1:200 in blocking solution and incubated for 2.5
h at RT. Nuclei were counterstained with DAPI for 30 min. Images were
acquired on glass-wells with Leica TCS SP2, TCS SP2 AOBS or TCS SP8 confocal
microscope with Las-X software (v3.5, Leica Biosystems) and processed using
ImageJ software (v1.52, NIH).
Mouse study approval. All mice have been maintained in a controlled environ-
ment, at 18–23 °C, 40–60% humidity and with 12-h dark/12-h light cycles, in a
certified animal facility under the control of the institutional organism for animal
welfare and ethical approach to animals in experimental procedures (Cogentech
OPBA). All animal studies were conducted with the approval of Italian Minister of
Health (27/2015-PR) and were performed in accordance with the Italian law (D.lgs.
26/2014), which enforces Dir. 2010/63/EU (Directive 2010/63/EU of the European
Parliament and of the Council of 22 September 2010 on the protection of animals
used for scientific purposes).
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Statistical analysis. A logistic regression analysis was used to correlate
EPN3 status with clinico-pathological parameters. The endpoints evaluated were
CI-LR and CI-DM. The CI-LR and CI-DM functions were estimated according to
methods described by Kalbfleisch and Prentice70, taking into account the com-
peting causes of recurrence. The hazard ratios (HR) comparison of EPN3-high vs.
low tumors were estimated with a Cox proportional hazards multivariable model
adjusted for Grade (G1-G2 and G3), Ki-67 (Ki-67 < 14% and Ki-67 ≥ 14%),
ERBB2 status (positive and negative), estrogen/progesterone receptor status [not
expressed (Both 0) and expressed (ER > 0 or PgR>0)], tumor size (pT1a/b, pT1c,
pT2, pT3/pT4), number of positive lymph nodes (pN0, pN1-2-3 and pNX) and age
at surgery (<50 and ≥50) (as appropriate in each subgroup analysis). All obser-
vations were truncated at 10 years from surgery. Analyses were carried out with the
SAS software (SAS Institute, Cary, NC) and the R software (v3.5, cran.r-project.
org/) with the “cmprsk” package developed by Gray (biowww.dfci.harvard.edu/
_gray). All reported P values are two-sided and P values <0.05 are considered as
significant.
Statistical analyses for RT-qPCR experiments, IB and IF quantifications, FACS
analyses, ELISA assays, mammosphere assays, radioactive internalization
experiments, Matrigel morphogenetic assays, soft agar, and invasion assays were
performed with Student’s t test two-tailed, on Excel Office 2019 software (v17.0,
Microsoft), with Each Pair Student’s t test two-tailed, on JMP software (v14, SAS
Institute), or with two-sided Fisher’s exact t test, on Graph Pad Prism 8, as
indicated in each figure legend. P values are shown as follows: *, <0.05; **, <0.01;
***, <0.001; ns, not significant. Quantitative data are presented as bars showing the
mean of independent biological replicates ± S.D. or as box plots. Each box plot (in
Figs. 3a, 4e, 5a, 7f, 7g, 9d; Supplementary Fig. 2D, E) is defined by 25 and 75
percentiles, showing median, whiskers representing 10 and 90 percentiles and
outliers if present.
Reproducibility. Experiments such as IB, IF, IHC, phase-contrast microscopy
images of cells (in Figs. 1c, 2a, b, g, 3b, 4a, f, 5c, 6c, 7a, b, d, 8e, g, 9a, b, c, e, 10a;
Supplementary Figs. 1A, 1B, 3A, 3D, 3E, 4A, 6A, 6B, 6D, 7A, 7C, 9B, 10C) are
representative of at least two independent experiments with similar results, unless
otherwise indicated.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data are available in the paper, in the Supplementary Information, or in Source Data
file. The source data underlying Figs. 1–10, Supplementary Figs 1–10 and Supplementary
Tables 1–3 are provided as a Source Data file. Source data are provided with this paper.
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